var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FEUK4Z2Y3%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FEUK4Z2Y3%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FEUK4Z2Y3%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
  2. \n
  3. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
  4. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2022\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study.\n \n \n \n \n\n\n \n Foster, J.; Beasley, R.; Braithwaite, I.; Harrison, T.; Holliday, M.; Pavord, I.; and Reddel, H.\n\n\n \n\n\n\n BMJ Open, 12(1): e048537. January 2022.\n \n\n\n\n
\n\n\n\n \n \n \"PerspectivesPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{foster_perspectives_2022,\n\ttitle = {Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study},\n\tvolume = {12},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens},\n\turl = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-048537},\n\tdoi = {10.1136/bmjopen-2020-048537},\n\tabstract = {Objectives\n              As-needed low-dose combination budesonide-formoterol is recommended by asthma guidelines in many countries as an alternative to maintenance inhaled corticosteroids (ICS) for treatment of mild asthma, but there are few data on patient attitudes toward these regimens. This study explored the comparative implementation experiences and future treatment preferences of mild asthma patients who had experienced these two treatment regimens.\n            \n            \n              Setting\n              A subgroup of adults randomised to maintenance ICS or as-needed ICS-formoterol in a multinational, 52-week open-label randomised controlled trial (NovelSTART) in mild asthma patients were interviewed to explore their motivations for treatment use during the study and their preferences for future treatment.\n            \n            \n              Participants\n              Semistructured interviews were conducted with 74 participants (Maintenance group: n=39, As-needed group n=35, mean age 38 (range 19–69)) and thematically analysed from transcribed audiorecordings.\n            \n            \n              Results\n              Emergent themes from analysis comprised: ‘How much my asthma affects me’ (how their asthma’s impact affected their self-management motivation); ‘What I know about asthma’ (limited knowledge impeded appropriate self-management decision making); ‘How much effort this treatment regimen involves for me’ (treatment complexity and/or difficulty establishing a medication routine impeded implementation, particularly in the Maintenance group); and ‘My beliefs about the benefits and risks of this treatment’ (patients who considered their treatment as ineffective, eg, limited difference in symptoms relative to salbutamol (both groups) or slower onset of relief (As-needed group) had poor motivation to use the treatment). Due to the simplicity of the as-needed combination strategy, this was the preferred future regimen, even by patients who had not yet tried it.\n            \n            \n              Conclusions\n              Key patient perspectives on the implementation of preventer treatments for mild asthma included factors relating to perceived asthma burden, disease knowledge, treatment complexity and treatment usefulness or safety. The as-needed budesonide-formoterol regimen was preferred to maintenance ICS treatment in mild asthma though patient education is urgently needed to address implementation motivation.\n            \n            \n              Trial registration number\n              ACTRN12615000999538.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2022-03-27},\n\tjournal = {BMJ Open},\n\tauthor = {Foster, Juliet and Beasley, Richard and Braithwaite, Irene and Harrison, Tim and Holliday, Mark and Pavord, Ian and Reddel, Helen},\n\tmonth = jan,\n\tyear = {2022},\n\tpages = {e048537},\n}\n\n
\n
\n\n\n
\n Objectives As-needed low-dose combination budesonide-formoterol is recommended by asthma guidelines in many countries as an alternative to maintenance inhaled corticosteroids (ICS) for treatment of mild asthma, but there are few data on patient attitudes toward these regimens. This study explored the comparative implementation experiences and future treatment preferences of mild asthma patients who had experienced these two treatment regimens. Setting A subgroup of adults randomised to maintenance ICS or as-needed ICS-formoterol in a multinational, 52-week open-label randomised controlled trial (NovelSTART) in mild asthma patients were interviewed to explore their motivations for treatment use during the study and their preferences for future treatment. Participants Semistructured interviews were conducted with 74 participants (Maintenance group: n=39, As-needed group n=35, mean age 38 (range 19–69)) and thematically analysed from transcribed audiorecordings. Results Emergent themes from analysis comprised: ‘How much my asthma affects me’ (how their asthma’s impact affected their self-management motivation); ‘What I know about asthma’ (limited knowledge impeded appropriate self-management decision making); ‘How much effort this treatment regimen involves for me’ (treatment complexity and/or difficulty establishing a medication routine impeded implementation, particularly in the Maintenance group); and ‘My beliefs about the benefits and risks of this treatment’ (patients who considered their treatment as ineffective, eg, limited difference in symptoms relative to salbutamol (both groups) or slower onset of relief (As-needed group) had poor motivation to use the treatment). Due to the simplicity of the as-needed combination strategy, this was the preferred future regimen, even by patients who had not yet tried it. Conclusions Key patient perspectives on the implementation of preventer treatments for mild asthma included factors relating to perceived asthma burden, disease knowledge, treatment complexity and treatment usefulness or safety. The as-needed budesonide-formoterol regimen was preferred to maintenance ICS treatment in mild asthma though patient education is urgently needed to address implementation motivation. Trial registration number ACTRN12615000999538.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE).\n \n \n \n \n\n\n \n Couillard, S.; Do, W. I. H.; Beasley, R.; Hinks, T. S.; and Pavord, I. D.\n\n\n \n\n\n\n ERJ Open Research, 8(1): 00570–2021. January 2022.\n \n\n\n\n
\n\n\n\n \n \n \"PredictingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{couillard_predicting_2022,\n\ttitle = {Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype {Oxford} {Asthma} {Attack} {Risk} {Scale} ({ORACLE})},\n\tvolume = {8},\n\tissn = {2312-0541},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00570-2021},\n\tdoi = {10.1183/23120541.00570-2021},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2022-03-27},\n\tjournal = {ERJ Open Research},\n\tauthor = {Couillard, Simon and Do, William Il Hoon and Beasley, Richard and Hinks, Timothy S.C. and Pavord, Ian D.},\n\tmonth = jan,\n\tyear = {2022},\n\tpages = {00570--2021},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.\n \n \n \n \n\n\n \n Beasley, R.; Harrison, T.; Peterson, S.; Gustafson, P.; Hamblin, A.; Bengtsson, T.; and Fagerås, M.\n\n\n \n\n\n\n JAMA Network Open, 5(3): e220615. March 2022.\n \n\n\n\n
\n\n\n\n \n \n \"EvaluationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_evaluation_2022,\n\ttitle = {Evaluation of {Budesonide}-{Formoterol} for {Maintenance} and {Reliever} {Therapy} {Among} {Patients} {With} {Poorly} {Controlled} {Asthma}: {A} {Systematic} {Review} and {Meta}-analysis},\n\tvolume = {5},\n\tissn = {2574-3805},\n\tshorttitle = {Evaluation of {Budesonide}-{Formoterol} for {Maintenance} and {Reliever} {Therapy} {Among} {Patients} {With} {Poorly} {Controlled} {Asthma}},\n\turl = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789512},\n\tdoi = {10.1001/jamanetworkopen.2022.0615},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2022-03-04},\n\tjournal = {JAMA Network Open},\n\tauthor = {Beasley, Richard and Harrison, Tim and Peterson, Stefan and Gustafson, Per and Hamblin, Angus and Bengtsson, Thomas and Fagerås, Malin},\n\tmonth = mar,\n\tyear = {2022},\n\tpages = {e220615},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial.\n \n \n \n \n\n\n \n Kearns, N.; Bruce, P.; Williams, M.; Doppen, M.; Black, M.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal,2102309. February 2022.\n \n\n\n\n
\n\n\n\n \n \n \"RepeatedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{kearns_repeated_2022,\n\ttitle = {Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: {A} randomised cross-over trial},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Repeated dose budesonide/formoterol compared to salbutamol in adult asthma},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02309-2021},\n\tdoi = {10.1183/13993003.02309-2021},\n\tabstract = {Objective\n              \n                To determine the comparative bronchodilator, systemic beta\n                2\n                -agonist, cardiovascular and adverse effects of salbutamol 200 µg and budesonide/formoterol 200/6 µg when taken repeatedly in stable asthma.\n              \n            \n            \n              Methods\n              \n                This open-label, cross-over, single-centre, controlled trial, randomised adults with asthma to different orders of two treatment regimens: salbutamol 200 µg\n                via\n                MDI at t=0, 30, 60, 90 min, then salbutamol 2.5 mg\n                via\n                nebuliser at t=120, 140, 160 and 420 min; or budesonide/formoterol 200/6 µg one actuation\n                via\n                Turbuhaler at t=0, 30, 60, 90 min, two actuations at t=120, 140, 160 and 420 min. The primary outcome measure was FEV\n                1\n                after 180 min. Secondary outcomes included repeat measures of FEV\n                1\n                , serum potassium, heart rate, and adverse events\n              \n            \n            \n              Results\n              \n                Of 39 patients randomised, two withdrew due to adverse events (QT\n                CF\n                prolongation and T wave abnormalities) after the first intervention with salbutamol. The mean (\n                sd\n                ) change from baseline FEV\n                1\n                180 min after randomisation for salbutamol and budesonide/formoterol regimens was 0.71 (0.46) L, N=38, and 0.58 (0.45) L, N=37, respectively; with a mean (\n                sd\n                ) paired difference of −0.10 (0.40) L, N=37, and a model-based estimated difference (95\\% CI) −0.12 (−0.25 to 0.02) L, p=0.088. In the main secondary analysis, salbutamol resulted in significantly greater FEV\n                1\n                from 30 to 240 min, but lesser FEV\n                1\n                at 360 and 420 min. Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events.\n              \n            \n            \n              Conclusion\n              \n                The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose\n                −1\n                and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta\n                2\n                -agonist and cardiovascular effects and more adverse events.},\n\tlanguage = {en},\n\turldate = {2022-03-04},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Kearns, Nethmi and Bruce, Pepa and Williams, Mathew and Doppen, Marjan and Black, Melissa and Weatherall, Mark and Beasley, Richard},\n\tmonth = feb,\n\tyear = {2022},\n\tpages = {2102309},\n}\n\n
\n
\n\n\n
\n Objective To determine the comparative bronchodilator, systemic beta 2 -agonist, cardiovascular and adverse effects of salbutamol 200 µg and budesonide/formoterol 200/6 µg when taken repeatedly in stable asthma. Methods This open-label, cross-over, single-centre, controlled trial, randomised adults with asthma to different orders of two treatment regimens: salbutamol 200 µg via MDI at t=0, 30, 60, 90 min, then salbutamol 2.5 mg via nebuliser at t=120, 140, 160 and 420 min; or budesonide/formoterol 200/6 µg one actuation via Turbuhaler at t=0, 30, 60, 90 min, two actuations at t=120, 140, 160 and 420 min. The primary outcome measure was FEV 1 after 180 min. Secondary outcomes included repeat measures of FEV 1 , serum potassium, heart rate, and adverse events Results Of 39 patients randomised, two withdrew due to adverse events (QT CF prolongation and T wave abnormalities) after the first intervention with salbutamol. The mean ( sd ) change from baseline FEV 1 180 min after randomisation for salbutamol and budesonide/formoterol regimens was 0.71 (0.46) L, N=38, and 0.58 (0.45) L, N=37, respectively; with a mean ( sd ) paired difference of −0.10 (0.40) L, N=37, and a model-based estimated difference (95% CI) −0.12 (−0.25 to 0.02) L, p=0.088. In the main secondary analysis, salbutamol resulted in significantly greater FEV 1 from 30 to 240 min, but lesser FEV 1 at 360 and 420 min. Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events. Conclusion The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose −1 and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta 2 -agonist and cardiovascular effects and more adverse events.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2021\n \n \n (16)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n SMART for the treatment of asthma: A network meta-analysis of real-world evidence.\n \n \n \n \n\n\n \n Rogliani, P.; Beasley, R.; Cazzola, M.; and Calzetta, L.\n\n\n \n\n\n\n Respiratory Medicine, 188: 106611. November 2021.\n \n\n\n\n
\n\n\n\n \n \n \"SMARTPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{rogliani_smart_2021,\n\ttitle = {{SMART} for the treatment of asthma: {A} network meta-analysis of real-world evidence},\n\tvolume = {188},\n\tissn = {09546111},\n\tshorttitle = {{SMART} for the treatment of asthma},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S095461112100319X},\n\tdoi = {10.1016/j.rmed.2021.106611},\n\tlanguage = {en},\n\turldate = {2022-03-27},\n\tjournal = {Respiratory Medicine},\n\tauthor = {Rogliani, Paola and Beasley, Richard and Cazzola, Mario and Calzetta, Luigino},\n\tmonth = nov,\n\tyear = {2021},\n\tpages = {106611},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Enhanced airway sensory nerve reactivity in non-eosinophilic asthma.\n \n \n \n \n\n\n \n Ali, H.; Brooks, C.; Crane, J.; Beasley, R.; Holgate, S.; Gibson, P.; Pattemore, P.; Tzeng, Y.; Stanley, T.; Pearce, N.; and Douwes, J.\n\n\n \n\n\n\n BMJ Open Respiratory Research, 8(1): e000974. November 2021.\n \n\n\n\n
\n\n\n\n \n \n \"EnhancedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{ali_enhanced_2021,\n\ttitle = {Enhanced airway sensory nerve reactivity in non-eosinophilic asthma},\n\tvolume = {8},\n\tissn = {2052-4439},\n\turl = {https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2021-000974},\n\tdoi = {10.1136/bmjresp-2021-000974},\n\tabstract = {Background\n              Neural mechanisms may play an important role in non-eosinophilic asthma (NEA). This study compared airway sensory nerve reactivity, using capsaicin challenge, in eosinophilic asthma (EA) and NEA and non-asthmatics.\n            \n            \n              Methods\n              \n                Thirty-eight asthmatics and 19 non-asthmatics (aged 14–21 years) underwent combined hypertonic saline challenge/sputum induction, fractional exhaled nitric oxide, atopy and spirometry tests, followed by capsaicin challenge. EA and NEA were defined using a sputum eosinophil cut-point of 2.5\\%. Airway hyperreactivity was defined as a ≥15\\% drop in FEV\n                1\n                during saline challenge. Sensory nerve reactivity was defined as the lowest capsaicin concentration that evoked 5 (C5) coughs.\n              \n            \n            \n              Results\n              \n                Non-eosinophilic asthmatics (n=20) had heightened capsaicin sensitivity (lower C5) compared with non-asthmatics (n=19) (geometric mean C5: 58.3 µM, 95\\% CI 24.1 to 141.5 vs 193.6 µM, 82.2 to 456.0; p{\\textless}0.05). NEA tended to also have greater capsaicin sensitivity than EA, with the difference in capsaicin sensitivity between NEA and EA being of similar magnitude (58.3 µM, 24.1 to 141.5 vs 191.0 µM, 70.9 to 514.0) to that observed between NEA and non-asthmatics; however, this did not reach statistical significance (p=0.07). FEV\n                1\n                was significantly reduced from baseline following capsaicin inhalation in both asthmatics and non-asthmatics but no differences were found between subgroups. No associations with capsaicin sensitivity and atopy, sputum eosinophils, blood eosinophils, asthma control or treatment were observed.\n              \n            \n            \n              Conclusion\n              NEA, but not EA, showed enhanced capsaicin sensitivity compared with non-asthmatics. Sensory nerve reactivity may therefore play an important role in the pathophysiology of NEA.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2022-03-27},\n\tjournal = {BMJ Open Respiratory Research},\n\tauthor = {Ali, Hajar and Brooks, Collin and Crane, Julian and Beasley, Richard and Holgate, Stephen and Gibson, Peter and Pattemore, Philip and Tzeng, Yu-Chieh and Stanley, Thorsten and Pearce, Neil and Douwes, Jeroen},\n\tmonth = nov,\n\tyear = {2021},\n\tpages = {e000974},\n}\n\n
\n
\n\n\n
\n Background Neural mechanisms may play an important role in non-eosinophilic asthma (NEA). This study compared airway sensory nerve reactivity, using capsaicin challenge, in eosinophilic asthma (EA) and NEA and non-asthmatics. Methods Thirty-eight asthmatics and 19 non-asthmatics (aged 14–21 years) underwent combined hypertonic saline challenge/sputum induction, fractional exhaled nitric oxide, atopy and spirometry tests, followed by capsaicin challenge. EA and NEA were defined using a sputum eosinophil cut-point of 2.5%. Airway hyperreactivity was defined as a ≥15% drop in FEV 1 during saline challenge. Sensory nerve reactivity was defined as the lowest capsaicin concentration that evoked 5 (C5) coughs. Results Non-eosinophilic asthmatics (n=20) had heightened capsaicin sensitivity (lower C5) compared with non-asthmatics (n=19) (geometric mean C5: 58.3 µM, 95% CI 24.1 to 141.5 vs 193.6 µM, 82.2 to 456.0; p\\textless0.05). NEA tended to also have greater capsaicin sensitivity than EA, with the difference in capsaicin sensitivity between NEA and EA being of similar magnitude (58.3 µM, 24.1 to 141.5 vs 191.0 µM, 70.9 to 514.0) to that observed between NEA and non-asthmatics; however, this did not reach statistical significance (p=0.07). FEV 1 was significantly reduced from baseline following capsaicin inhalation in both asthmatics and non-asthmatics but no differences were found between subgroups. No associations with capsaicin sensitivity and atopy, sputum eosinophils, blood eosinophils, asthma control or treatment were observed. Conclusion NEA, but not EA, showed enhanced capsaicin sensitivity compared with non-asthmatics. Sensory nerve reactivity may therefore play an important role in the pathophysiology of NEA.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Asthma in the anti-inflammatory reliever therapy era.\n \n \n \n \n\n\n \n Baggott, C.; and Beasley, R.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 9(2): 118–119. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"AsthmaPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{baggott_asthma_2021,\n\ttitle = {Asthma in the anti-inflammatory reliever therapy era},\n\tvolume = {9},\n\tissn = {22132600},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020304653},\n\tdoi = {10.1016/S2213-2600(20)30465-3},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2022-03-27},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Baggott, Christina and Beasley, Richard},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {118--119},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Asthma and COVID-19: Preconceptions about Predisposition.\n \n \n \n \n\n\n \n Beasley, R.; Hills, T.; and Kearns, N.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 203(7): 799–801. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"AsthmaPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_asthma_2021,\n\ttitle = {Asthma and {COVID}-19: {Preconceptions} about {Predisposition}},\n\tvolume = {203},\n\tissn = {1073-449X, 1535-4970},\n\tshorttitle = {Asthma and {COVID}-19},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.202102-0266ED},\n\tdoi = {10.1164/rccm.202102-0266ED},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2022-03-04},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Hills, Thomas and Kearns, Nethmi},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {799--801},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Respiratory syncytial virus: paying the immunity debt with interest.\n \n \n \n \n\n\n \n Hatter, L.; Eathorne, A.; Hills, T.; Bruce, P.; and Beasley, R.\n\n\n \n\n\n\n The Lancet Child & Adolescent Health,S2352464221003333. October 2021.\n \n\n\n\n
\n\n\n\n \n \n \"RespiratoryPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hatter_respiratory_2021,\n\ttitle = {Respiratory syncytial virus: paying the immunity debt with interest},\n\tissn = {23524642},\n\tshorttitle = {Respiratory syncytial virus},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2352464221003333},\n\tdoi = {10.1016/S2352-4642(21)00333-3},\n\tlanguage = {en},\n\turldate = {2021-10-28},\n\tjournal = {The Lancet Child \\& Adolescent Health},\n\tauthor = {Hatter, Lee and Eathorne, Allie and Hills, Thomas and Bruce, Pepa and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2021},\n\tpages = {S2352464221003333},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Has the time come to end use of the blue inhaler?.\n \n \n \n \n\n\n \n Bush, A.; Dalziel, S. R; Byrnes, C. A; Hatter, L.; and Beasley, R.\n\n\n \n\n\n\n The Lancet Respiratory Medicine,S2213260021001855. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"HasPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{bush_has_2021,\n\ttitle = {Has the time come to end use of the blue inhaler?},\n\tissn = {22132600},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260021001855},\n\tdoi = {10.1016/S2213-2600(21)00185-5},\n\tlanguage = {en},\n\turldate = {2021-05-02},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Bush, Andrew and Dalziel, Stuart R and Byrnes, Catherine A and Hatter, Lee and Beasley, Richard},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {S2213260021001855},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma.\n \n \n \n \n\n\n \n Papi, A.; Braithwaite, I.; Ebmeier, S.; Hancox, R. J.; Harrison, T.; Holliday, M.; Houghton, C.; Morandi, L.; Oldfield, K.; Pavord, I. D.; Reddel, H. K.; Williams, M.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 57(2): 2003064. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Budesonide–formoterolPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{papi_budesonideformoterol_2021,\n\ttitle = {Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma},\n\tvolume = {57},\n\tissn = {0903-1936, 1399-3003},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03064-2020},\n\tdoi = {10.1183/13993003.03064-2020},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2021-04-30},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Papi, Alberto and Braithwaite, Irene and Ebmeier, Stefan and Hancox, Robert J. and Harrison, Tim and Holliday, Mark and Houghton, Claire and Morandi, Luca and Oldfield, Karen and Pavord, Ian D. and Reddel, Helen K. and Williams, Mathew and Weatherall, Mark and Beasley, Richard},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {2003064},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD.\n \n \n \n \n\n\n \n Karlsson, N.; Atkinson, M. J.; Müllerová, H.; Alacqua, M.; Keen, C.; Hughes, R.; Janson, C.; Make, B.; Price, D.; and Reddel, H. K.\n\n\n \n\n\n\n ERJ Open Research, 7(1): 00828–2020. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ValidationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{karlsson_validation_2021,\n\ttitle = {Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or {COPD}},\n\tvolume = {7},\n\tissn = {2312-0541},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00828-2020},\n\tdoi = {10.1183/23120541.00828-2020},\n\tabstract = {Background\n              The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD).\n            \n            \n              Methods\n              \n                Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study (\n                ClinicalTrials.gov\n                :\n                NCT02760329\n                ). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses.\n              \n            \n            \n              Results\n              \n                For the total sample, the mean±\n                sd\n                RSQ score was 5.6±4.3 (range 0–16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76–0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of –2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7–2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p{\\textless}0.001).\n              \n            \n            \n              Conclusions\n              The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-30},\n\tjournal = {ERJ Open Research},\n\tauthor = {Karlsson, Niklas and Atkinson, Mark J. and Müllerová, Hana and Alacqua, Marianna and Keen, Christina and Hughes, Rod and Janson, Christer and Make, Barry and Price, David and Reddel, Helen K.},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {00828--2020},\n}\n\n
\n
\n\n\n
\n Background The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD). Methods Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study ( ClinicalTrials.gov : NCT02760329 ). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses. Results For the total sample, the mean± sd RSQ score was 5.6±4.3 (range 0–16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76–0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of –2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7–2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p\\textless0.001). Conclusions The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Balancing the needs of the many and the few: where next for adult asthma guidelines?.\n \n \n \n \n\n\n \n Shaw, D. E; Heaney, L. G; Thomas, M.; Beasley, R.; Gibson, P. G; and Pavord, I. D\n\n\n \n\n\n\n The Lancet Respiratory Medicine,S2213260021000217. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"BalancingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{shaw_balancing_2021,\n\ttitle = {Balancing the needs of the many and the few: where next for adult asthma guidelines?},\n\tissn = {22132600},\n\tshorttitle = {Balancing the needs of the many and the few},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260021000217},\n\tdoi = {10.1016/S2213-2600(21)00021-7},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Shaw, Dominick E and Heaney, Liam G and Thomas, Mike and Beasley, Richard and Gibson, Peter G and Pavord, Ian D},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {S2213260021000217},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.\n \n \n \n \n\n\n \n Reddel, H. K; Vestbo, J.; Agustí, A.; Anderson, G. P; Bansal, A. T; Beasley, R.; Bel, E. H; Janson, C.; Make, B.; Pavord, I. D; Price, D.; Rapsomaniki, E.; Karlsson, N.; Finch, D. K; Nuevo, J.; de Giorgio-Miller, A.; Alacqua, M.; Hughes, R.; Müllerová, H.; and Gerhardsson de Verdier, M.\n\n\n \n\n\n\n European Respiratory Journal,2003927. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"HeterogeneityPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{reddel_heterogeneity_2021,\n\ttitle = {Heterogeneity within and between physician-diagnosed asthma and/or {COPD}: {NOVELTY} cohort},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Heterogeneity within and between physician-diagnosed asthma and/or {COPD}},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03927-2020},\n\tdoi = {10.1183/13993003.03927-2020},\n\tabstract = {Background\n              Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort.\n            \n            \n              Methods\n              Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated using ordinal logistic regression analysis.\n            \n            \n              Results\n              \n                Of 11 243 patients, 5940 (52.8\\%) had physician-assigned asthma, 1396 (12.4\\%) had asthma+COPD and 3907 (34.8\\%) had COPD; almost half were from primary care. Symptoms, health-related quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma+COPD and COPD, with 23\\%, 62\\% and 64\\% of patients, respectively, having post-bronchodilator FEV\n                1\n                /FVC {\\textless}lower limit of normal.\n              \n              Symptoms and exacerbations increased with greater physician-assessed severity, and were higher in asthma+COPD, but 24.3\\% with mild asthma and 20.4\\% with mild COPD had experienced ≥1 exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment relative to severity. Blood eosinophil counts varied little across diagnosis/severity groups, but blood neutrophil counts increased with severity across all diagnoses.\n            \n            \n              Conclusion\n              This analysis demonstrates marked heterogeneity within, and overlap between, physician-assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have specific risks and treatment implications.},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Reddel, Helen K and Vestbo, Jørgen and Agustí, Alvar and Anderson, Gary P and Bansal, Aruna T and Beasley, Richard and Bel, Elisabeth H and Janson, Christer and Make, Barry and Pavord, Ian D and Price, David and Rapsomaniki, Eleni and Karlsson, Niklas and Finch, Donna K and Nuevo, Javier and de Giorgio-Miller, Alex and Alacqua, Marianna and Hughes, Rod and Müllerová, Hana and Gerhardsson de Verdier, Maria},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {2003927},\n}\n\n
\n
\n\n\n
\n Background Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort. Methods Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated using ordinal logistic regression analysis. Results Of 11 243 patients, 5940 (52.8%) had physician-assigned asthma, 1396 (12.4%) had asthma+COPD and 3907 (34.8%) had COPD; almost half were from primary care. Symptoms, health-related quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma+COPD and COPD, with 23%, 62% and 64% of patients, respectively, having post-bronchodilator FEV 1 /FVC \\textlesslower limit of normal. Symptoms and exacerbations increased with greater physician-assessed severity, and were higher in asthma+COPD, but 24.3% with mild asthma and 20.4% with mild COPD had experienced ≥1 exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment relative to severity. Blood eosinophil counts varied little across diagnosis/severity groups, but blood neutrophil counts increased with severity across all diagnoses. Conclusion This analysis demonstrates marked heterogeneity within, and overlap between, physician-assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have specific risks and treatment implications.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n More options for managing severe asthma in adults.\n \n \n \n \n\n\n \n Chang, A. B; and Beasley, R.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 9(1): 3–5. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"MorePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{chang_more_2021,\n\ttitle = {More options for managing severe asthma in adults},\n\tvolume = {9},\n\tissn = {22132600},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020303982},\n\tdoi = {10.1016/S2213-2600(20)30398-2},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-28},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Chang, Anne B and Beasley, Richard},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {3--5},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.\n \n \n \n \n\n\n \n Braithwaite, I. E.; Cai, F.; Tom, J. A.; Galanter, J. M.; Owen, R. P.; Zhu, R.; Williams, M.; McGregor, A. G.; Eliahu, A.; Durk, M. R.; Dengler, H. S.; Zak, M.; Kenny, J. R.; Wilson, M. E.; Beasley, R.; and Chen, H.\n\n\n \n\n\n\n Journal of Allergy and Clinical Immunology,S009167492100422X. March 2021.\n \n\n\n\n
\n\n\n\n \n \n \"InhaledPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{braithwaite_inhaled_2021,\n\ttitle = {Inhaled {JAK} inhibitor {GDC}-0214 reduces exhaled nitric oxide in patients with mild asthma: {A} randomized, controlled, proof-of-activity trial},\n\tissn = {00916749},\n\tshorttitle = {Inhaled {JAK} inhibitor {GDC}-0214 reduces exhaled nitric oxide in patients with mild asthma},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S009167492100422X},\n\tdoi = {10.1016/j.jaci.2021.02.042},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {Journal of Allergy and Clinical Immunology},\n\tauthor = {Braithwaite, Irene E. and Cai, Fang and Tom, Jennifer A. and Galanter, Joshua M. and Owen, Ryan P. and Zhu, Rui and Williams, Mathew and McGregor, Anna G. and Eliahu, Avi and Durk, Matthew R. and Dengler, Hart S. and Zak, Mark and Kenny, Jane R. and Wilson, Maria E. and Beasley, Richard and Chen, Hubert},\n\tmonth = mar,\n\tyear = {2021},\n\tpages = {S009167492100422X},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The Vexed Problem of Corticosteroid Toxicity in Asthma: Time for Standardized Assessment.\n \n \n \n \n\n\n \n Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 9(1): 373–374. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_vexed_2021,\n\ttitle = {The {Vexed} {Problem} of {Corticosteroid} {Toxicity} in {Asthma}: {Time} for {Standardized} {Assessment}},\n\tvolume = {9},\n\tissn = {22132198},\n\tshorttitle = {The {Vexed} {Problem} of {Corticosteroid} {Toxicity} in {Asthma}},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213219820309193},\n\tdoi = {10.1016/j.jaip.2020.09.001},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-28},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Beasley, Richard and Weatherall, Mark},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {373--374},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Asthma and COVID-19: Preconceptions about Predisposition.\n \n \n \n \n\n\n \n Beasley, R.; Hills, T.; and Kearns, N.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 203(7): 799–801. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"AsthmaPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_asthma_2021-1,\n\ttitle = {Asthma and {COVID}-19: {Preconceptions} about {Predisposition}},\n\tvolume = {203},\n\tissn = {1073-449X, 1535-4970},\n\tshorttitle = {Asthma and {COVID}-19},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.202102-0266ED},\n\tdoi = {10.1164/rccm.202102-0266ED},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2021-04-28},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Hills, Thomas and Kearns, Nethmi},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {799--801},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n ICS-formoterol reliever versus ICS and short-acting β2 -agonist reliever in asthma: a systematic review and meta-analysis.\n \n \n \n \n\n\n \n Hatter, L.; Bruce, P.; Braithwaite, I.; Holliday, M.; James Fingleton; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n ERJ Open Research, 7(1): 00701–2020. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ICS-formoterolPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hatter_ics-formoterol_2021,\n\ttitle = {{ICS}-formoterol reliever versus {ICS} and short-acting β2 -agonist reliever in asthma: a systematic review and meta-analysis},\n\tvolume = {7},\n\tissn = {2312-0541},\n\tshorttitle = {{ICS}-formoterol reliever \\textit{versus} {ICS} and short-acting β $_{\\textrm{2}}$ -agonist reliever in asthma},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00701-2020},\n\tdoi = {10.1183/23120541.00701-2020},\n\tabstract = {Background\n              \n                The Global Initiative for Asthma recommends as-needed inhaled corticosteroid (ICS)-formoterol as an alternative to maintenance ICS plus short-acting β\n                2\n                -agonist (SABA) reliever at step 2 of its stepwise treatment algorithm. Our aim was to assess the efficacy and safety of these two treatment regimens, with a focus on prevention of severe exacerbation.\n              \n            \n            \n              Methods\n              We performed a systematic review and meta-analysis of all randomised controlled trials (RCTs) comparing as-needed ICS-formoterol with maintenance ICS plus SABA. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrials.gov were searched from database inception to 12 December 2019. The primary outcome was time to first severe exacerbation. RCTs were excluded if they used as-needed budesonide-formoterol as part of a maintenance and reliever regimen, or did not report on severe exacerbations. The review is registered with PROSPERO (identifier number CRD42020154680).\n            \n            \n              Results\n              Four RCTs (n=8065 participants) were included in the analysis. As-needed ICS-formoterol was associated with a prolonged time to first severe exacerbation (hazard ratio 0.85, 95\\% CI 0.73–1.00; p=0.048) and reduced daily ICS dose (mean difference −177.3 μg, 95\\% CI −182.2–−172.4 μg). Asthma symptom control was worse in the as-needed group (Asthma Control Questionnaire-5 mean difference 0.12, 95\\% CI 0.09–0.14), although this did not meet the minimal clinically important difference of 0.50 units. There was no significant difference in serious adverse events (OR 1.07, 95\\% CI 0.84–1.36).\n            \n            \n              Conclusion\n              As-needed ICS-formoterol offers a therapeutic alternative to maintenance low-dose ICS plus SABA in asthma and may be the preferred option when prevention of severe exacerbation is the primary aim of treatment.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-28},\n\tjournal = {ERJ Open Research},\n\tauthor = {Hatter, Lee and Bruce, Pepa and Braithwaite, Irene and Holliday, Mark and {James Fingleton} and Weatherall, Mark and Beasley, Richard},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {00701--2020},\n}\n\n
\n
\n\n\n
\n Background The Global Initiative for Asthma recommends as-needed inhaled corticosteroid (ICS)-formoterol as an alternative to maintenance ICS plus short-acting β 2 -agonist (SABA) reliever at step 2 of its stepwise treatment algorithm. Our aim was to assess the efficacy and safety of these two treatment regimens, with a focus on prevention of severe exacerbation. Methods We performed a systematic review and meta-analysis of all randomised controlled trials (RCTs) comparing as-needed ICS-formoterol with maintenance ICS plus SABA. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrials.gov were searched from database inception to 12 December 2019. The primary outcome was time to first severe exacerbation. RCTs were excluded if they used as-needed budesonide-formoterol as part of a maintenance and reliever regimen, or did not report on severe exacerbations. The review is registered with PROSPERO (identifier number CRD42020154680). Results Four RCTs (n=8065 participants) were included in the analysis. As-needed ICS-formoterol was associated with a prolonged time to first severe exacerbation (hazard ratio 0.85, 95% CI 0.73–1.00; p=0.048) and reduced daily ICS dose (mean difference −177.3 μg, 95% CI −182.2–−172.4 μg). Asthma symptom control was worse in the as-needed group (Asthma Control Questionnaire-5 mean difference 0.12, 95% CI 0.09–0.14), although this did not meet the minimal clinically important difference of 0.50 units. There was no significant difference in serious adverse events (OR 1.07, 95% CI 0.84–1.36). Conclusion As-needed ICS-formoterol offers a therapeutic alternative to maintenance low-dose ICS plus SABA in asthma and may be the preferred option when prevention of severe exacerbation is the primary aim of treatment.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The management of mild asthma.\n \n \n \n \n\n\n \n O'Byrne, P. M.; Reddel, H. K.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 57(4): 2003051. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{obyrne_management_2021,\n\ttitle = {The management of mild asthma},\n\tvolume = {57},\n\tissn = {0903-1936, 1399-3003},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03051-2020},\n\tdoi = {10.1183/13993003.03051-2020},\n\tabstract = {Inhaled corticosteroids (ICSs) have been recommended as a maintenance treatment, either alone or together with long-acting inhaled β\n              2\n              -agonists, for all asthma patients. Short-acting β\n              2\n              -agonists (SABAs) are rapid-onset bronchodilators, which provide symptom relief, but have no anti-inflammatory properties, yet are the most widely used as-needed reliever treatment for asthma and often the only treatment prescribed. Asthma patients can find adhering to daily preventative medication with ICS difficult and will often revert to using as-needed SABA as their only treatment, increasing their risk of exacerbations. The purpose of this review is to evaluate the efficacy of reliever medications that contain ICS compared with SABA as reliever, or with maintenance ICS and SABA as reliever, in mild asthma patients.\n            \n            Nine studies were identified that have evaluated the use of ICS as a component of an as-needed reliever in patients with mild asthma. Four of the most recent studies compared the combination of ICS/formoterol to SABA as reliever.\n            ICS-containing reliever medication was superior to SABA as reliever alone, and was equivalent to maintenance ICS and SABA as reliever, particularly in reducing risks of severe asthma exacerbations, in studies which compared these reliever options.\n            SABAs should not be used as a reliever without ICS. The concern about patients with mild asthma not being adherent to maintenance ICS supports a recommendation that ICS/formoterol should be considered as a treatment option instead of maintenance ICS, to avoid the risk of patients reverting to SABA alone.},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2021-04-11},\n\tjournal = {European Respiratory Journal},\n\tauthor = {O'Byrne, Paul M. and Reddel, Helen K. and Beasley, Richard},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {2003051},\n}\n\n
\n
\n\n\n
\n Inhaled corticosteroids (ICSs) have been recommended as a maintenance treatment, either alone or together with long-acting inhaled β 2 -agonists, for all asthma patients. Short-acting β 2 -agonists (SABAs) are rapid-onset bronchodilators, which provide symptom relief, but have no anti-inflammatory properties, yet are the most widely used as-needed reliever treatment for asthma and often the only treatment prescribed. Asthma patients can find adhering to daily preventative medication with ICS difficult and will often revert to using as-needed SABA as their only treatment, increasing their risk of exacerbations. The purpose of this review is to evaluate the efficacy of reliever medications that contain ICS compared with SABA as reliever, or with maintenance ICS and SABA as reliever, in mild asthma patients. Nine studies were identified that have evaluated the use of ICS as a component of an as-needed reliever in patients with mild asthma. Four of the most recent studies compared the combination of ICS/formoterol to SABA as reliever. ICS-containing reliever medication was superior to SABA as reliever alone, and was equivalent to maintenance ICS and SABA as reliever, particularly in reducing risks of severe asthma exacerbations, in studies which compared these reliever options. SABAs should not be used as a reliever without ICS. The concern about patients with mild asthma not being adherent to maintenance ICS supports a recommendation that ICS/formoterol should be considered as a treatment option instead of maintenance ICS, to avoid the risk of patients reverting to SABA alone.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (16)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Patient experiences of as-needed budesonide-formoterol by Turbuhaler® for treatment of mild asthma; a qualitative study.\n \n \n \n \n\n\n \n Foster, J.; Beasley, R.; Braithwaite, I.; Harrison, T.; Holliday, M.; Pavord, I.; and Reddel, H.\n\n\n \n\n\n\n Respiratory Medicine, 175: 106154. December 2020.\n \n\n\n\n
\n\n\n\n \n \n \"PatientPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{foster_patient_2020,\n\ttitle = {Patient experiences of as-needed budesonide-formoterol by {Turbuhaler}® for treatment of mild asthma; a qualitative study},\n\tvolume = {175},\n\tissn = {09546111},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0954611120302948},\n\tdoi = {10.1016/j.rmed.2020.106154},\n\tlanguage = {en},\n\turldate = {2021-05-12},\n\tjournal = {Respiratory Medicine},\n\tauthor = {Foster, J.M. and Beasley, R. and Braithwaite, I. and Harrison, T. and Holliday, M. and Pavord, I. and Reddel, H.K.},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {106154},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice.\n \n \n \n \n\n\n \n Beasley, R.; Harper, J.; and Masoli, M.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 8(5): 425–427. May 2020.\n \n\n\n\n
\n\n\n\n \n \n \"Anti-interleukin-5Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_anti-interleukin-5_2020,\n\ttitle = {Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice},\n\tvolume = {8},\n\tissn = {22132600},\n\tshorttitle = {Anti-interleukin-5 therapy in patients with severe asthma},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020300515},\n\tdoi = {10.1016/S2213-2600(20)30051-5},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-07},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Harper, James and Masoli, Matthew},\n\tmonth = may,\n\tyear = {2020},\n\tpages = {425--427},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Twenty‐five years of Respirology: Advances in asthma.\n \n \n \n \n\n\n \n Beasley, R.; and Gibson, P.\n\n\n \n\n\n\n Respirology, 25(1): 11–13. January 2020.\n \n\n\n\n
\n\n\n\n \n \n \"Twenty‐fivePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_twentyfive_2020,\n\ttitle = {Twenty‐five years of {Respirology}: {Advances} in asthma},\n\tvolume = {25},\n\tissn = {1323-7799, 1440-1843},\n\tshorttitle = {Twenty‐five years of \\textit{{Respirology}}},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13735},\n\tdoi = {10.1111/resp.13735},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-07},\n\tjournal = {Respirology},\n\tauthor = {Beasley, Richard and Gibson, Peter},\n\tmonth = jan,\n\tyear = {2020},\n\tpages = {11--13},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.\n \n \n \n \n\n\n \n Beasley, R.; Braithwaite, I.; Semprini, A.; Kearns, C.; Weatherall, M.; Harrison, T. W.; Papi, A.; and Pavord, I. D.\n\n\n \n\n\n\n European Respiratory Journal, 55(1): 1901407. January 2020.\n \n\n\n\n
\n\n\n\n \n \n \"ICS-formoterolPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_ics-formoterol_2020,\n\ttitle = {{ICS}-formoterol reliever therapy stepwise treatment algorithm for adult asthma},\n\tvolume = {55},\n\tissn = {0903-1936, 1399-3003},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01407-2019},\n\tdoi = {10.1183/13993003.01407-2019},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-07},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Beasley, Richard and Braithwaite, Irene and Semprini, Alex and Kearns, Ciléin and Weatherall, Mark and Harrison, Tim W. and Papi, Alberto and Pavord, Ian D.},\n\tmonth = jan,\n\tyear = {2020},\n\tpages = {1901407},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial.\n \n \n \n \n\n\n \n Baggott, C.; Reddel, H. K.; Hardy, J.; Sparks, J.; Holliday, M.; Corin, A.; Montgomery, B.; Reid, J.; Sheahan, D.; Hancox, R. J.; Weatherall, M.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n European Respiratory Journal, 55(4): 1902073. April 2020.\n \n\n\n\n
\n\n\n\n \n \n \"PatientPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{baggott_patient_2020,\n\ttitle = {Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the {PRACTICAL} study, a randomised clinical trial},\n\tvolume = {55},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02073-2019},\n\tdoi = {10.1183/13993003.02073-2019},\n\tabstract = {Symptom-driven low-dose inhaled corticosteroid–formoterol is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma. However, there are no data on patient preferences for this regimen.\n            A subgroup of participants in the PRACTICAL study (ACTRN12616000377437), a randomised controlled trial comparing symptom-driven budesonide–formoterol with maintenance budesonide plus as-needed terbutaline completed a survey on treatment preferences, satisfaction, beliefs and experience at their final study visit.\n            306 (75\\%) out of 407 eligible participants completed the survey. Regimen preference was strongly associated with randomised treatment, as were preferences for and beliefs about preventer inhaler use. Combination preventer and reliever as-needed therapy was preferred by 135 (90\\%, 95\\% CI 85.2–94.8\\%) out of 150 who were randomised to as-needed budesonide–formoterol, and by 63 (40\\%, 95\\% CI 32.7–48.1\\%) out of 156 who were randomised to maintenance budesonide. By contrast, twice-daily preventer inhaler with a reliever inhaler as required was preferred by 15 (10\\%) out of 150 of those randomised to as-needed budesonide–formoterol and 93 (60\\%) out of 156 of those randomised to maintenance budesonide. Satisfaction with all study inhalers was high. Of patients randomised to as-needed budesonide–formoterol 92\\% (n=138) were confident using it as a reliever at the end of the study.\n            Although most participants preferred the regimen to which they had been randomised, this association was much stronger for those randomised to budesonide–formoterol as needed, indicating that most patients preferred as-needed corticosteroid–formoterol therapy if they had experienced it.},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2021-05-07},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Baggott, Christina and Reddel, Helen K. and Hardy, Jo and Sparks, Jenny and Holliday, Mark and Corin, Andrew and Montgomery, Barney and Reid, Jim and Sheahan, Davitt and Hancox, Robert J. and Weatherall, Mark and Beasley, Richard and Fingleton, James},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {1902073},\n}\n\n
\n
\n\n\n
\n Symptom-driven low-dose inhaled corticosteroid–formoterol is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma. However, there are no data on patient preferences for this regimen. A subgroup of participants in the PRACTICAL study (ACTRN12616000377437), a randomised controlled trial comparing symptom-driven budesonide–formoterol with maintenance budesonide plus as-needed terbutaline completed a survey on treatment preferences, satisfaction, beliefs and experience at their final study visit. 306 (75%) out of 407 eligible participants completed the survey. Regimen preference was strongly associated with randomised treatment, as were preferences for and beliefs about preventer inhaler use. Combination preventer and reliever as-needed therapy was preferred by 135 (90%, 95% CI 85.2–94.8%) out of 150 who were randomised to as-needed budesonide–formoterol, and by 63 (40%, 95% CI 32.7–48.1%) out of 156 who were randomised to maintenance budesonide. By contrast, twice-daily preventer inhaler with a reliever inhaler as required was preferred by 15 (10%) out of 150 of those randomised to as-needed budesonide–formoterol and 93 (60%) out of 156 of those randomised to maintenance budesonide. Satisfaction with all study inhalers was high. Of patients randomised to as-needed budesonide–formoterol 92% (n=138) were confident using it as a reliever at the end of the study. Although most participants preferred the regimen to which they had been randomised, this association was much stronger for those randomised to budesonide–formoterol as needed, indicating that most patients preferred as-needed corticosteroid–formoterol therapy if they had experienced it.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n What matters most to patients when choosing treatment for mild–moderate asthma? Results from a discrete choice experiment.\n \n \n \n \n\n\n \n Baggott, C.; Hansen, P.; Hancox, R. J; Hardy, J. K.; Sparks, J.; Holliday, M.; Weatherall, M.; Beasley, R.; Reddel, H. K; and Fingleton, J.\n\n\n \n\n\n\n Thorax, 75(10): 842–848. October 2020.\n \n\n\n\n
\n\n\n\n \n \n \"WhatPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{baggott_what_2020,\n\ttitle = {What matters most to patients when choosing treatment for mild–moderate asthma? {Results} from a discrete choice experiment},\n\tvolume = {75},\n\tissn = {0040-6376, 1468-3296},\n\tshorttitle = {What matters most to patients when choosing treatment for mild–moderate asthma?},\n\turl = {https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2019-214343},\n\tdoi = {10.1136/thoraxjnl-2019-214343},\n\tabstract = {Background\n              An as-needed combination preventer and reliever regimen was recently introduced as an alternative to conventional daily preventer treatment for mild asthma. In a subgroup analysis of the PRACTICAL study, a pragmatic randomised controlled trial of budesonide–formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild asthma, we recently reported that about two-thirds preferred as-needed combination preventer and reliever therapy. The aim of this study was to determine the relative importance of attributes associated with these two asthma therapies in this subgroup of participants who indicated their preferred treatment in the PRACTICAL study.\n            \n            \n              Methods\n              At their final study visit, a subgroup of participants indicated their preferred treatment and completed a discrete choice experiment using the Potentially All Pairwise RanKings of all possible Alternatives method and 1000minds software. Treatment attributes and their levels were selected from measurable study outcomes, and included: treatment regimen, shortness of breath, steroid dose and likelihood of asthma flare-up.\n            \n            \n              Results\n              The final analysis dataset included 288 participants, 64\\% of whom preferred as-needed combination preventer and reliever. Of the attributes, no shortness of breath and lowest risk of asthma flare-up were ranked highest and second highest, respectively. However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment.\n            \n            \n              Conclusions\n              Knowledge of patient preferences for treatment attributes together with regimen characteristics can be used in shared decision-making regarding choice of treatment for patients with mild–moderate asthma.\n            \n            \n              Trial registration number\n              ACTRN12616000377437.},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2021-05-05},\n\tjournal = {Thorax},\n\tauthor = {Baggott, Christina and Hansen, Paul and Hancox, Robert J and Hardy, Jo Katherine and Sparks, Jenny and Holliday, Mark and Weatherall, Mark and Beasley, Richard and Reddel, Helen K and Fingleton, James},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {842--848},\n}\n\n
\n
\n\n\n
\n Background An as-needed combination preventer and reliever regimen was recently introduced as an alternative to conventional daily preventer treatment for mild asthma. In a subgroup analysis of the PRACTICAL study, a pragmatic randomised controlled trial of budesonide–formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild asthma, we recently reported that about two-thirds preferred as-needed combination preventer and reliever therapy. The aim of this study was to determine the relative importance of attributes associated with these two asthma therapies in this subgroup of participants who indicated their preferred treatment in the PRACTICAL study. Methods At their final study visit, a subgroup of participants indicated their preferred treatment and completed a discrete choice experiment using the Potentially All Pairwise RanKings of all possible Alternatives method and 1000minds software. Treatment attributes and their levels were selected from measurable study outcomes, and included: treatment regimen, shortness of breath, steroid dose and likelihood of asthma flare-up. Results The final analysis dataset included 288 participants, 64% of whom preferred as-needed combination preventer and reliever. Of the attributes, no shortness of breath and lowest risk of asthma flare-up were ranked highest and second highest, respectively. However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment. Conclusions Knowledge of patient preferences for treatment attributes together with regimen characteristics can be used in shared decision-making regarding choice of treatment for patients with mild–moderate asthma. Trial registration number ACTRN12616000377437.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma.\n \n \n \n\n\n \n Hardy, J.; Tewhaiti-Smith, J.; Baggott, C.; Fingleton, J.; Semprini, A.; Holliday, M.; Hancox, R. J.; Weatherall, M.; and Harwood, M.\n\n\n \n\n\n\n The New Zealand Medical Journal, 133(1520): 61–72. August 2020.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n
@article{hardy_combination_2020,\n\ttitle = {Combination budesonide/formoterol inhaler as sole reliever therapy in {Māori} and {Pacific} people with mild and moderate asthma},\n\tvolume = {133},\n\tissn = {1175-8716},\n\tabstract = {AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes.\nMETHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable.\nRESULTS: Seventy-two participants (8\\%) identified as Māori, 36 participants (4\\%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70).\nCONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.},\n\tlanguage = {eng},\n\tnumber = {1520},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Hardy, Jo and Tewhaiti-Smith, Jordan and Baggott, Christina and Fingleton, James and Semprini, Alex and Holliday, Mark and Hancox, Robert J. and Weatherall, Mark and Harwood, Matire},\n\tmonth = aug,\n\tyear = {2020},\n\tpmid = {32994594},\n\tkeywords = {Administration, Inhalation, Adult, Anti-Asthmatic Agents, Asthma, Bronchodilator Agents, Budesonide, Budesonide, Formoterol Fumarate Drug Combination, Case-Control Studies, Disease Progression, Drug Therapy, Combination, Ethnic Groups, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, New Zealand, Outcome Assessment, Health Care, Terbutaline, Treatment Outcome},\n\tpages = {61--72},\n}\n\n
\n
\n\n\n
\n AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Patient preferences for asthma management: a qualitative study.\n \n \n \n \n\n\n \n Baggott, C.; Chan, A.; Hurford, S.; Fingleton, J.; Beasley, R.; Harwood, M.; Reddel, H. K; and Levack, W. M. M.\n\n\n \n\n\n\n BMJ Open, 10(8): e037491. August 2020.\n Number: 8\n\n\n\n
\n\n\n\n \n \n \"PatientPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{baggott_patient_2020-1,\n\ttitle = {Patient preferences for asthma management: a qualitative study},\n\tvolume = {10},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Patient preferences for asthma management},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-037491},\n\tdoi = {10.1136/bmjopen-2020-037491},\n\tabstract = {Objective\n              Preference for asthma management and the use of medications is motivated by the interplay between lived experiences of asthma and patients’ attitudes towards medications. Many previous studies have focused on individual aspects of asthma management, such as the use of preventer and reliever inhalers. The aim of this qualitative study was to explore the preferences of patients with mild-moderate asthma for asthma management as a whole and factors that influenced these preferences.\n            \n            \n              Design\n              A qualitative study employing qualitative descriptive analysis situated within a constructionist epistemology to analyse transcribed audio recordings from focus groups.\n            \n            \n              Setting\n              Three locations within the greater Wellington area in New Zealand.\n            \n            \n              Participants\n              \n                Twenty-seven adults with self-reported doctor’s diagnosis of asthma, taking short-acting beta-agonists alone or inhaled corticosteroids with or without long-acting beta\n                2\n                -agonist, who had used any inhaled asthma medication within the last month.\n              \n            \n            \n              Results\n              Four key areas described preferences for asthma management. Preferences for self-management: participants wanted to be in control of their asthma and developed personal strategies to achieve this. Preferences for the specific medications or treatment regimen: participants preferred regimens that were convenient and reliably relieved symptoms. Preferences for inhaler devices: devices that had dose counters and were easy to use and portable were important. Preferences for asthma services: participants wanted easier access to their inhalers and to be empowered by their healthcare providers. Participant preferences within each of these four areas were influenced by the impact asthma had on their life, their health beliefs, emotional consequences of asthma and perceived barriers to asthma management.\n            \n            \n              Conclusions\n              This study illustrates the interaction of the lived experience of asthma, factors specific to the individual, and factors relating to asthma treatments in shaping patient preferences for asthma management. This aids our understanding of preferences for asthma management from the patient perspective.\n            \n            \n              Trial registration number\n              Australian New Zealand Clinical Trials Registry (ACTRN12619000601134).},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2020-09-03},\n\tjournal = {BMJ Open},\n\tauthor = {Baggott, Christina and Chan, Amy and Hurford, Sally and Fingleton, James and Beasley, Richard and Harwood, Matire and Reddel, Helen K and Levack, William Mark Magnus},\n\tmonth = aug,\n\tyear = {2020},\n\tnote = {Number: 8},\n\tpages = {e037491},\n}\n\n
\n
\n\n\n
\n Objective Preference for asthma management and the use of medications is motivated by the interplay between lived experiences of asthma and patients’ attitudes towards medications. Many previous studies have focused on individual aspects of asthma management, such as the use of preventer and reliever inhalers. The aim of this qualitative study was to explore the preferences of patients with mild-moderate asthma for asthma management as a whole and factors that influenced these preferences. Design A qualitative study employing qualitative descriptive analysis situated within a constructionist epistemology to analyse transcribed audio recordings from focus groups. Setting Three locations within the greater Wellington area in New Zealand. Participants Twenty-seven adults with self-reported doctor’s diagnosis of asthma, taking short-acting beta-agonists alone or inhaled corticosteroids with or without long-acting beta 2 -agonist, who had used any inhaled asthma medication within the last month. Results Four key areas described preferences for asthma management. Preferences for self-management: participants wanted to be in control of their asthma and developed personal strategies to achieve this. Preferences for the specific medications or treatment regimen: participants preferred regimens that were convenient and reliably relieved symptoms. Preferences for inhaler devices: devices that had dose counters and were easy to use and portable were important. Preferences for asthma services: participants wanted easier access to their inhalers and to be empowered by their healthcare providers. Participant preferences within each of these four areas were influenced by the impact asthma had on their life, their health beliefs, emotional consequences of asthma and perceived barriers to asthma management. Conclusions This study illustrates the interaction of the lived experience of asthma, factors specific to the individual, and factors relating to asthma treatments in shaping patient preferences for asthma management. This aids our understanding of preferences for asthma management from the patient perspective. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12619000601134).\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial.\n \n \n \n \n\n\n \n Baggott, C.; Hardy, J.; Sparks, J.; Holliday, M.; Hall, D.; Vohlidkova, A.; Hancox, R. J.; Weatherall, M.; Fingleton, J.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 56(4): 2000170. October 2020.\n Number: 4\n\n\n\n
\n\n\n\n \n \n \"Self-titrationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{baggott_self-titration_2020,\n\ttitle = {Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the {PRACTICAL} randomised controlled trial},\n\tvolume = {56},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Self-titration of inhaled corticosteroid and β $_{\\textrm{2}}$ -agonist in response to symptoms in mild asthma},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00170-2020},\n\tdoi = {10.1183/13993003.00170-2020},\n\tabstract = {Introduction\n              \n                In mild asthma, as-needed budesonide–formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β\n                2\n                -agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and β\n                2\n                -agonist use in PRACTICAL, a randomised controlled trial.\n              \n            \n            \n              Methods\n              \n                Participants were randomised 1:1 to as-needed budesonide–formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks. 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and β\n                2\n                -agonist use. One actuation of budesonide–formoterol was considered to be an equivalent bronchodilator dose as two actuations of terbutaline.\n              \n            \n            \n              Results\n              \n                Participants randomised to as-needed budesonide–formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156\n                versus\n                22 days, respectively), lower median daily budesonide dose (164\n                versus\n                328 μg, respectively) and a greater median number of days of ≥4 budesonide actuations (4\n                versus\n                1 days, respectively). Participants randomised to as-needed budesonide–formoterol took higher equivalent doses of β\n                2\n                -agonist both overall (median number of actuations 0.8\n                versus\n                0.3 per day, respectively) and in response to worsening asthma (total number of “overuse days” of {\\textgreater}8 or {\\textgreater}16 actuations of budesonide–formoterol or terbutaline 33\n                versus\n                10 days, respectively).\n              \n            \n            \n              Conclusions\n              \n                The timing of ICS dose when self-titrated to β\n                2\n                -agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed β\n                2\n                -agonist.},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2020-10-13},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Baggott, Christina and Hardy, Jo and Sparks, Jenny and Holliday, Mark and Hall, Daniela and Vohlidkova, Alexandra and Hancox, Robert J. and Weatherall, Mark and Fingleton, James and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2020},\n\tnote = {Number: 4},\n\tpages = {2000170},\n}\n\n
\n
\n\n\n
\n Introduction In mild asthma, as-needed budesonide–formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β 2 -agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and β 2 -agonist use in PRACTICAL, a randomised controlled trial. Methods Participants were randomised 1:1 to as-needed budesonide–formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks. 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and β 2 -agonist use. One actuation of budesonide–formoterol was considered to be an equivalent bronchodilator dose as two actuations of terbutaline. Results Participants randomised to as-needed budesonide–formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156 versus 22 days, respectively), lower median daily budesonide dose (164 versus 328 μg, respectively) and a greater median number of days of ≥4 budesonide actuations (4 versus 1 days, respectively). Participants randomised to as-needed budesonide–formoterol took higher equivalent doses of β 2 -agonist both overall (median number of actuations 0.8 versus 0.3 per day, respectively) and in response to worsening asthma (total number of “overuse days” of \\textgreater8 or \\textgreater16 actuations of budesonide–formoterol or terbutaline 33 versus 10 days, respectively). Conclusions The timing of ICS dose when self-titrated to β 2 -agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed β 2 -agonist.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Inhaled Corticosteroids in Acute Asthma: A Systemic Review and Meta-Analysis.\n \n \n \n \n\n\n \n Kearns, N.; Maijers, I.; Harper, J.; Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 8(2): 605–617.e6. February 2020.\n Number: 2\n\n\n\n
\n\n\n\n \n \n \"InhaledPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{kearns_inhaled_2020,\n\ttitle = {Inhaled {Corticosteroids} in {Acute} {Asthma}: {A} {Systemic} {Review} and {Meta}-{Analysis}},\n\tvolume = {8},\n\tissn = {22132198},\n\tshorttitle = {Inhaled {Corticosteroids} in {Acute} {Asthma}},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213219819307767},\n\tdoi = {10.1016/j.jaip.2019.08.051},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-09-28},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Kearns, Nethmi and Maijers, Ingrid and Harper, James and Beasley, Richard and Weatherall, Mark},\n\tmonth = feb,\n\tyear = {2020},\n\tnote = {Number: 2},\n\tpages = {605--617.e6},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Reducing the burden of asthma: time to set research and clinical priorities.\n \n \n \n \n\n\n \n Beasley, R.; and Hancox, R. J\n\n\n \n\n\n\n The Lancet Respiratory Medicine,S2213260020304008. September 2020.\n \n\n\n\n
\n\n\n\n \n \n \"ReducingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_reducing_2020,\n\ttitle = {Reducing the burden of asthma: time to set research and clinical priorities},\n\tissn = {22132600},\n\tshorttitle = {Reducing the burden of asthma},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020304008},\n\tdoi = {10.1016/S2213-2600(20)30400-8},\n\tlanguage = {en},\n\turldate = {2020-09-11},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Hancox, Robert J},\n\tmonth = sep,\n\tyear = {2020},\n\tpages = {S2213260020304008},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Nasal gene expression changes with inhaled corticosteroid treatment in asthma.\n \n \n \n\n\n \n Boudewijn, I. M.; Lan, A.; Faiz, A.; Cox, C. A.; Brouwer, S.; Schokker, S.; Vroegop, S. J.; Nawijn, M. C.; Woodruff, P. G.; Christenson, S. A.; Hagedoorn, P.; Frijlink, H. W.; Choy, D. F.; Brouwer, U.; Wisman, M.; Postma, D. S.; Fingleton, J.; Beasley, R.; van den Berge, M.; and Guryev, V.\n\n\n \n\n\n\n Allergy, 75(1): 191–194. 2020.\n Number: 1\n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{boudewijn_nasal_2020,\n\ttitle = {Nasal gene expression changes with inhaled corticosteroid treatment in asthma},\n\tvolume = {75},\n\tissn = {1398-9995},\n\tdoi = {10.1111/all.13952},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Allergy},\n\tauthor = {Boudewijn, Ilse M. and Lan, Andy and Faiz, Alen and Cox, Claire A. and Brouwer, Sharon and Schokker, Siebrig and Vroegop, Sebastiaan J. and Nawijn, Martijn C. and Woodruff, Prescott G. and Christenson, Stephanie A. and Hagedoorn, Paul and Frijlink, Henderik W. and Choy, David F. and Brouwer, Uilke and Wisman, Marissa and Postma, Dirkje S. and Fingleton, James and Beasley, Richard and van den Berge, Maarten and Guryev, Victor},\n\tyear = {2020},\n\tpmid = {31230369},\n\tnote = {Number: 1},\n\tpages = {191--194},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Anti‐inflammatory reliever therapy in asthma: The evidence mounts but more is needed.\n \n \n \n \n\n\n \n Bruce, P.; Hatter, L.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 25(8): 776–778. August 2020.\n Number: 8\n\n\n\n
\n\n\n\n \n \n \"Anti‐inflammatoryPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{bruce_antiinflammatory_2020,\n\ttitle = {Anti‐inflammatory reliever therapy in asthma: {The} evidence mounts but more is needed},\n\tvolume = {25},\n\tissn = {1323-7799, 1440-1843},\n\tshorttitle = {Anti‐inflammatory reliever therapy in asthma},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13889},\n\tdoi = {10.1111/resp.13889},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2020-07-15},\n\tjournal = {Respirology},\n\tauthor = {Bruce, Pepa and Hatter, Lee and Beasley, Richard},\n\tmonth = aug,\n\tyear = {2020},\n\tnote = {Number: 8},\n\tpages = {776--778},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The history and future of short‐acting beta 2 ‐agonist therapy in asthma.\n \n \n \n \n\n\n \n Hills, T.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 25(3): 246–248. March 2020.\n Number: 3\n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hills_history_2020,\n\ttitle = {The history and future of short‐acting beta 2 ‐agonist therapy in asthma},\n\tvolume = {25},\n\tissn = {1323-7799},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13727},\n\tdoi = {10.1111/resp.13727},\n\tnumber = {3},\n\tjournal = {Respirology},\n\tauthor = {Hills, Thomas and Beasley, Richard},\n\tmonth = mar,\n\tyear = {2020},\n\tnote = {Number: 3},\n\tpages = {246--248},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.\n \n \n \n \n\n\n \n Maijers, I.; Kearns, N.; Harper, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 55(1): 1901147. January 2020.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"OralPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{maijers_oral_2020,\n\ttitle = {Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma},\n\tvolume = {55},\n\tissn = {0903-1936},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01147-2019},\n\tdoi = {10.1183/13993003.01147-2019},\n\tnumber = {1},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Maijers, Ingrid and Kearns, Nethmi and Harper, James and Weatherall, Mark and Beasley, Richard},\n\tmonth = jan,\n\tyear = {2020},\n\tnote = {Number: 1},\n\tkeywords = {Asthma},\n\tpages = {1901147},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Optimal Asthma Control: Time for a New Target.\n \n \n \n \n\n\n \n Beasley, R.; Braithwaite, I.; Semprini, A.; Kearns, C.; Weatherall, M.; and Pavord, I. D\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine,rccm.201910–1934CI. January 2020.\n \n\n\n\n
\n\n\n\n \n \n \"OptimalPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{beasley_optimal_2020,\n\ttitle = {Optimal {Asthma} {Control}: {Time} for a {New} {Target}},\n\tissn = {1073-449X},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.201910-1934CI},\n\tdoi = {10.1164/rccm.201910-1934CI},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Braithwaite, Irene and Semprini, Alex and Kearns, Ciléin and Weatherall, Mark and Pavord, Ian D},\n\tmonth = jan,\n\tyear = {2020},\n\tkeywords = {Asthma},\n\tpages = {rccm.201910--1934CI},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2019\n \n \n (10)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Change in biomarkers of type-2 inflammation following severe exacerbations of asthma.\n \n \n \n \n\n\n \n Semprini, R.; Shortt, N.; Ebmeier, S.; Semprini, A.; Varughese, R.; Holweg, C. T J; Matthews, J. G; Fingleton, J.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Thorax, 74(1): 95–98. January 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"ChangePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{semprini_change_2019,\n\ttitle = {Change in biomarkers of type-2 inflammation following severe exacerbations of asthma},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-211657},\n\tdoi = {10.1136/thoraxjnl-2018-211657},\n\tabstract = {We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10\n              9\n              /L, p{\\textless}0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p{\\textless}0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p{\\textless}0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.\n            \n            \n              Trial registration number\n              Post-results; The Australia New Zealand Trial Registry, {\\textgreater}ACTRN12614000443695.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Semprini, Ruth and Shortt, Nick and Ebmeier, Stefan and Semprini, Alex and Varughese, Rachel and Holweg, Cecile T J and Matthews, John G and Fingleton, James and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tmonth = jan,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {95--98},\n}\n\n
\n
\n\n\n
\n We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p\\textless0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p\\textless0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p\\textless0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma. Trial registration number Post-results; The Australia New Zealand Trial Registry, \\textgreaterACTRN12614000443695.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Combined impact of healthy lifestyle factors on risk of asthma, rhinoconjunctivitis and eczema in school children: ISAAC phase III.\n \n \n \n \n\n\n \n Morales, E.; Strachan, D.; Asher, I.; Ellwood, P.; Pearce, N.; and Garcia-Marcos, L.\n\n\n \n\n\n\n Thorax, 74(6): 531–538. June 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n \"CombinedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{morales_combined_2019,\n\ttitle = {Combined impact of healthy lifestyle factors on risk of asthma, rhinoconjunctivitis and eczema in school children: {ISAAC} phase {III}},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\tshorttitle = {Combined impact of healthy lifestyle factors on risk of asthma, rhinoconjunctivitis and eczema in school children},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-212668},\n\tdoi = {10.1136/thoraxjnl-2018-212668},\n\tabstract = {Background\n              Asthma is not the key focus of prevention strategies. A Healthy Lifestyle Index (HLI) was developed to examine the combined effect of modifiable lifestyle factors on asthma, rhinoconjunctivitis and eczema using data from the International Study of Asthma and Allergies in Childhood (ISAAC) phase III.\n            \n            \n              Methods\n              Information on symptoms of asthma, rhinoconjunctivitis, eczema and several lifestyle factors was obtained from children aged 6–7 years through written questionnaires. The HLI combined five lifestyle factors: no parental smoking, child’s adherence to Mediterranean diet, child’s healthy body mass index, high physical activity and non-sedentary behaviour. The association between the HLI and risk of asthma, rhinoconjunctivitis and eczema was evaluated using multilevel mixed-effects logistic regression models.\n            \n            \n              Findings\n              Data of 70 795 children from 37 centres in 19 countries were analysed. Each additional healthy lifestyle factor was associated with a reduced risk of current wheeze (OR 0.87, 95\\% CI 0.84 to 0.89), asthma ever (OR 0.89, 95\\% CI 0.87 to 0.92), current symptoms of rhinoconjunctivitis (OR 0.95, 95\\% CI 0.92 to 0.97) and current symptoms of eczema (OR 0.92, 95\\% CI 0.92 to 0.98). Theoretically, if associations were causal, a combination of four or five healthy lifestyle factors would result into a reduction up to 16\\% of asthma cases (ranging from 2.7\\% to 26.3 \\% according to region of the world).\n            \n            \n              Conclusions\n              These findings should be interpreted with caution given the limitations to infer causality from cross-sectional observational data. Efficacy of interventions to improve multiple modifiable lifestyle factors to reduce the burden asthma and allergy in childhood should be assessed.},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Morales, Eva and Strachan, David and Asher, Innes and Ellwood, Philippa and Pearce, Neil and Garcia-Marcos, Luis},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {531--538},\n}\n\n
\n
\n\n\n
\n Background Asthma is not the key focus of prevention strategies. A Healthy Lifestyle Index (HLI) was developed to examine the combined effect of modifiable lifestyle factors on asthma, rhinoconjunctivitis and eczema using data from the International Study of Asthma and Allergies in Childhood (ISAAC) phase III. Methods Information on symptoms of asthma, rhinoconjunctivitis, eczema and several lifestyle factors was obtained from children aged 6–7 years through written questionnaires. The HLI combined five lifestyle factors: no parental smoking, child’s adherence to Mediterranean diet, child’s healthy body mass index, high physical activity and non-sedentary behaviour. The association between the HLI and risk of asthma, rhinoconjunctivitis and eczema was evaluated using multilevel mixed-effects logistic regression models. Findings Data of 70 795 children from 37 centres in 19 countries were analysed. Each additional healthy lifestyle factor was associated with a reduced risk of current wheeze (OR 0.87, 95% CI 0.84 to 0.89), asthma ever (OR 0.89, 95% CI 0.87 to 0.92), current symptoms of rhinoconjunctivitis (OR 0.95, 95% CI 0.92 to 0.97) and current symptoms of eczema (OR 0.92, 95% CI 0.92 to 0.98). Theoretically, if associations were causal, a combination of four or five healthy lifestyle factors would result into a reduction up to 16% of asthma cases (ranging from 2.7% to 26.3 % according to region of the world). Conclusions These findings should be interpreted with caution given the limitations to infer causality from cross-sectional observational data. Efficacy of interventions to improve multiple modifiable lifestyle factors to reduce the burden asthma and allergy in childhood should be assessed.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.\n \n \n \n \n\n\n \n Hardy, J.; Baggott, C.; Fingleton, J.; Reddel, H. K; Hancox, R. J; Harwood, M.; Corin, A.; Sparks, J.; Hall, D.; Sabbagh, D.; Mane, S.; Vohlidkova, A.; Martindale, J.; Williams, M.; Shirtcliffe, P.; Holliday, M.; Weatherall, M.; Beasley, R.; Corin, A.; Dronfield, L.; Helm, C.; Paterson, T.; Poudel, B.; Dyer, M.; Jasinski, C.; Sheahan, D.; Sheahan, P.; Gailer, N.; Van Zuilen, J.; Basa, A.; Devereaux, C.; Egan, K.; Haughey, S.; Marks, R.; Venter, D.; Zhang, H.; Trevithick, K.; Williams, M.; Williams, P.; Baggott, C.; Beasley, R.; Braithwaite, I.; Eathorne, A.; Ebmeier, S.; Fingleton, J.; Hall, D.; Hardy, J.; Harwood, M.; Holliday, M.; Houghton, C.; Mane, S.; Martindale, J.; Oldfield, K.; Pilcher, J.; Sabbagh, D.; Shirtcliffe, P.; Snively, S.; Sparks, J.; Vohlidkova, A.; Williams, M.; Collins, P.; Hassan, S.; Lam, A.; Lionnet, C.; Montgomery, B.; Smaill, L.; Moon, S.; Quinn, D.; Bayly-McCredie, E.; Millar-Coote, C.; Millar-Coote, D.; Reid, J.; Samuel, A.; Burton, N.; Mullard, T.; Tranquilino, T.; Watson, E.; Bell, J.; Harris, R.; Richmond, J.; Smith, S.; Krivan, B.; Robertson, C.; Hancox, R. J; Weatherall, M.; Glensor, S.; O'Connor, D.; Porrachia, A.; and Reddel, H. K\n\n\n \n\n\n\n The Lancet, 394(10202): 919–928. September 2019.\n Number: 10202\n\n\n\n
\n\n\n\n \n \n \"Budesonide-formoterolPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hardy_budesonide-formoterol_2019,\n\ttitle = {Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma ({PRACTICAL}): a 52-week, open-label, multicentre, superiority, randomised controlled trial},\n\tvolume = {394},\n\tissn = {01406736},\n\tshorttitle = {Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma ({PRACTICAL})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0140673619319488},\n\tdoi = {10.1016/S0140-6736(19)31948-8},\n\tlanguage = {en},\n\tnumber = {10202},\n\turldate = {2020-08-23},\n\tjournal = {The Lancet},\n\tauthor = {Hardy, Jo and Baggott, Christina and Fingleton, James and Reddel, Helen K and Hancox, Robert J and Harwood, Matire and Corin, Andrew and Sparks, Jenny and Hall, Daniela and Sabbagh, Doñah and Mane, Saras and Vohlidkova, Alexandra and Martindale, John and Williams, Mathew and Shirtcliffe, Philippa and Holliday, Mark and Weatherall, Mark and Beasley, Richard and Corin, Andrew and Dronfield, Liz and Helm, Colin and Paterson, Tracy and Poudel, Bhuwan and Dyer, Malcolm and Jasinski, Christine and Sheahan, Davitt and Sheahan, Pamela and Gailer, Nick and Van Zuilen, Jan and Basa, Andy and Devereaux, Christine and Egan, Karin and Haughey, Sneha and Marks, Rodney and Venter, Dirk and Zhang, Hank and Trevithick, Karen and Williams, Mike and Williams, Philippa and Baggott, Christina and Beasley, Richard and Braithwaite, Irene and Eathorne, Alexandra and Ebmeier, Stefan and Fingleton, James and Hall, Daniela and Hardy, Jo and Harwood, Matire and Holliday, Mark and Houghton, Claire and Mane, Saras and Martindale, John and Oldfield, Karen and Pilcher, Janine and Sabbagh, Doñah and Shirtcliffe, Philippa and Snively, Suzanne and Sparks, Jenny and Vohlidkova, Alexandra and Williams, Mathew and Collins, Patrick and Hassan, Summer and Lam, Annika and Lionnet, Claudette and Montgomery, Barney and Smaill, Liz and Moon, Stella and Quinn, Dean and Bayly-McCredie, Elena and Millar-Coote, Chris and Millar-Coote, Dean and Reid, Jim and Samuel, Anna and Burton, Nicola and Mullard, Tina and Tranquilino, Tyronne and Watson, Edward and Bell, Jill and Harris, Rachel and Richmond, John and Smith, Sue and Krivan, Brent and Robertson, Cheryl and Hancox, Robert J and Weatherall, Mark and Glensor, Sue and O'Connor, Dermot and Porrachia, Anne-Christine and Reddel, Helen K},\n\tmonth = sep,\n\tyear = {2019},\n\tnote = {Number: 10202},\n\tpages = {919--928},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma.\n \n \n \n \n\n\n \n Denton, E.; Hore-Lacy, F.; Radhakrishna, N.; Gilbert, A.; Tay, T.; Lee, J.; Dabscheck, E.; Harvey, E. S.; Bulathsinhala, L.; Fingleton, J.; Price, D.; Gibson, P. G.; O'Hehir, R.; and Hew, M.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 7(5): 1440–1449. May 2019.\n Number: 5\n\n\n\n
\n\n\n\n \n \n \"SeverePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{denton_severe_2019,\n\ttitle = {Severe {Asthma} {Global} {Evaluation} ({SAGE}): {An} {Electronic} {Platform} for {Severe} {Asthma}},\n\tvolume = {7},\n\tissn = {22132198},\n\tshorttitle = {Severe {Asthma} {Global} {Evaluation} ({SAGE})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S221321981930265X},\n\tdoi = {10.1016/j.jaip.2019.02.042},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Denton, Eve and Hore-Lacy, Fiona and Radhakrishna, Naghmeh and Gilbert, Annie and Tay, TunnRen and Lee, Joy and Dabscheck, Eli and Harvey, Erin S. and Bulathsinhala, Lakmini and Fingleton, James and Price, David and Gibson, Peter G. and O'Hehir, Robyn and Hew, Mark},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 5},\n\tpages = {1440--1449},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma.\n \n \n \n \n\n\n \n Beasley, R.; Harper, J.; Bird, G.; Dunphy, H.; Semprini, A.; Pavord, I. D.; Papi, A.; and Weatherall, M.\n\n\n \n\n\n\n BMC Pulmonary Medicine, 19(1): 264. December 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"Dose-responsePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_dose-response_2019,\n\ttitle = {Dose-response relationship of {ICS}/fast-onset {LABA} as reliever therapy in asthma},\n\tvolume = {19},\n\tissn = {1471-2466},\n\turl = {https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-019-1014-4},\n\tdoi = {10.1186/s12890-019-1014-4},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {BMC Pulmonary Medicine},\n\tauthor = {Beasley, Richard and Harper, James and Bird, Grace and Dunphy, Harriette and Semprini, Alex and Pavord, Ian D. and Papi, Alberto and Weatherall, Mark},\n\tmonth = dec,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {264},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma.\n \n \n \n \n\n\n \n Beasley, R.; Holliday, M.; Reddel, H. K.; Braithwaite, I.; Ebmeier, S.; Hancox, R. J.; Harrison, T.; Houghton, C.; Oldfield, K.; Papi, A.; Pavord, I. D.; Williams, M.; and Weatherall, M.\n\n\n \n\n\n\n New England Journal of Medicine, 380(21): 2020–2030. May 2019.\n Number: 21\n\n\n\n
\n\n\n\n \n \n \"ControlledPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_controlled_2019,\n\ttitle = {Controlled {Trial} of {Budesonide}–{Formoterol} as {Needed} for {Mild} {Asthma}},\n\tvolume = {380},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1901963},\n\tdoi = {10.1056/NEJMoa1901963},\n\tlanguage = {en},\n\tnumber = {21},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Beasley, Richard and Holliday, Mark and Reddel, Helen K. and Braithwaite, Irene and Ebmeier, Stefan and Hancox, Robert J. and Harrison, Tim and Houghton, Claire and Oldfield, Karen and Papi, Alberto and Pavord, Ian D. and Williams, Mathew and Weatherall, Mark},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 21},\n\tpages = {2020--2030},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Pragmatic Randomized Controlled Trial of Budesonide/Formoterol Reliever Therapy in Adults with Mild Asthma.\n \n \n \n\n\n \n Beasley, R W; Holliday, M; Reddel, H K; Braithwaite, I; Ebmeier, S; Hancox, R; Harrison, T; Houghton, C; Oldfield, K; and Papi, A\n\n\n \n\n\n\n In D101. CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD, pages A7477–A7477. American Thoracic Society, 2019.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@incollection{beasley_pragmatic_2019,\n\ttitle = {Pragmatic {Randomized} {Controlled} {Trial} of {Budesonide}/{Formoterol} {Reliever} {Therapy} in {Adults} with {Mild} {Asthma}},\n\tisbn = {1073-449X},\n\tbooktitle = {D101. {CLINICAL} {AND} {TRANSLATIONAL} {STUDIES} {IN} {ASTHMA} {AND} {COPD}},\n\tpublisher = {American Thoracic Society},\n\tauthor = {Beasley, R W and Holliday, M and Reddel, H K and Braithwaite, I and Ebmeier, S and Hancox, R and Harrison, T and Houghton, C and Oldfield, K and Papi, A},\n\tyear = {2019},\n\tpages = {A7477--A7477},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Triaging treatable traits in asthma.\n \n \n \n\n\n \n Baggott, C.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 24(1): 5–6. 2019.\n Number: 1 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{baggott_triaging_2019,\n\ttitle = {Triaging treatable traits in asthma},\n\tvolume = {24},\n\tissn = {1323-7799},\n\tnumber = {1},\n\tjournal = {Respirology},\n\tauthor = {Baggott, Christina and Beasley, Richard},\n\tyear = {2019},\n\tnote = {Number: 1\nPublisher: Wiley Online Library},\n\tpages = {5--6},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Asthma paradoxes: time for a new approach across the spectrum of asthma severity.\n \n \n \n\n\n \n Beasley, R.; Bird, G.; Harper, J.; and Weatherall, M.\n\n\n \n\n\n\n European Respiratory Journal, 53: 1900218. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_asthma_2019,\n\ttitle = {Asthma paradoxes: time for a new approach across the spectrum of asthma severity},\n\tvolume = {53},\n\tdoi = {10.1183/13993003.00218-2019},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Beasley, Richard and Bird, Grace and Harper, James and Weatherall, Mark},\n\tyear = {2019},\n\tpages = {1900218},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Inhaled Corticosteroid Therapy in Adult Asthma: Time for a New Therapeutic Dose Terminology.\n \n \n \n\n\n \n Beasley, R.; Harper, J.; Bird, G.; Maijers, I.; Weatherall, M.; and D Pavord, I.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_inhaled_2019,\n\ttitle = {Inhaled {Corticosteroid} {Therapy} in {Adult} {Asthma}: {Time} for a {New} {Therapeutic} {Dose} {Terminology}},\n\tdoi = {10.1164/rccm.201810-1868CI},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Harper, James and Bird, Grace and Maijers, Ingrid and Weatherall, Mark and D Pavord, Ian},\n\tyear = {2019},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2018\n \n \n (5)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma.\n \n \n \n\n\n \n Semprini, R.; Williams, M.; Semprini, A.; McDouall, A.; Fingleton, J.; Holweg, C.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 6. 2018.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{semprini_type_2018,\n\ttitle = {Type 2 {Biomarkers} and {Prediction} of {Future} {Exacerbations} and {Lung} {Function} {Decline} in {Adult} {Asthma}},\n\tvolume = {6},\n\tdoi = {10.1016/j.jaip.2018.03.004},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Semprini, Ruth and Williams, Mathew and Semprini, Alex and McDouall, Alice and Fingleton, James and Holweg, Cécile and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tyear = {2018},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The further paradoxes of asthma management: Time for a new approach across the spectrum of asthma severity.\n \n \n \n\n\n \n Beasley, R.; Bird, G.; Harper, J.; and Weatherall, M.\n\n\n \n\n\n\n European Respiratory Journal, 52: 1800694. 2018.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_further_2018,\n\ttitle = {The further paradoxes of asthma management: {Time} for a new approach across the spectrum of asthma severity},\n\tvolume = {52},\n\tdoi = {10.1183/13993003.00694-2018},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Beasley, Richard and Bird, Grace and Harper, James and Weatherall, Mark},\n\tyear = {2018},\n\tpages = {1800694},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The Clinical Relevance of Periostin in Asthma.\n \n \n \n\n\n \n Braithwaite, I.; Semprini, R.; and Beasley, R.\n\n\n \n\n\n\n Barcelona Respiratory Network, 4. 2018.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{braithwaite_clinical_2018,\n\ttitle = {The {Clinical} {Relevance} of {Periostin} in {Asthma}},\n\tvolume = {4},\n\tdoi = {10.23866/BRNRev:2017-0028},\n\tjournal = {Barcelona Respiratory Network},\n\tauthor = {Braithwaite, Irene and Semprini, Ruth and Beasley, Richard},\n\tyear = {2018},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Serum periostin levels following small bone fractures, long bone fractures and joint replacements: An observational study.\n \n \n \n\n\n \n Varughese, R.; Semprini, R.; Munro, C.; Fingleton, J.; Holweg, C.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Allergy, Asthma & Clinical Immunology, 14. 2018.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{varughese_serum_2018,\n\ttitle = {Serum periostin levels following small bone fractures, long bone fractures and joint replacements: {An} observational study},\n\tvolume = {14},\n\tdoi = {10.1186/s13223-018-0254-9},\n\tjournal = {Allergy, Asthma \\& Clinical Immunology},\n\tauthor = {Varughese, Rachel and Semprini, Ruth and Munro, Claire and Fingleton, James and Holweg, Cecile and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tyear = {2018},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Serum periostin levels in adults of Chinese descent: an observational study.\n \n \n \n\n\n \n Tan, E.; Varughese, R.; Semprini, R.; Montgomery, B.; Holweg, C.; Olsson, J.; Caswell-Smith, R.; Fingleton, J.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Allergy, Asthma & Clinical Immunology, 14. 2018.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{tan_serum_2018,\n\ttitle = {Serum periostin levels in adults of {Chinese} descent: an observational study},\n\tvolume = {14},\n\tdoi = {10.1186/s13223-018-0312-3},\n\tjournal = {Allergy, Asthma \\& Clinical Immunology},\n\tauthor = {Tan, Evan and Varughese, Rachel and Semprini, Ruth and Montgomery, Barney and Holweg, Cecile and Olsson, Julie and Caswell-Smith, Rachel and Fingleton, James and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tyear = {2018},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2017\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Vitamin D and asthma: a case to answer.\n \n \n \n\n\n \n Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 5(11): 839–840. 2017.\n Number: 11 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_vitamin_2017,\n\ttitle = {Vitamin {D} and asthma: a case to answer},\n\tvolume = {5},\n\tissn = {2213-2600},\n\tnumber = {11},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Weatherall, Mark},\n\tyear = {2017},\n\tnote = {Number: 11\nPublisher: Elsevier},\n\tpages = {839--840},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Trends in international asthma mortality: Analysis of data from the WHO Mortality Database from 46 countries (1993-2012).\n \n \n \n\n\n \n Ebmeier, S.; Thayabaran, D.; Braithwaite, I.; Bénamara, C.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n The Lancet, 390. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{ebmeier_trends_2017,\n\ttitle = {Trends in international asthma mortality: {Analysis} of data from the {WHO} {Mortality} {Database} from 46 countries (1993-2012)},\n\tvolume = {390},\n\tdoi = {10.1016/S0140-6736(17)31448-4},\n\tjournal = {The Lancet},\n\tauthor = {Ebmeier, Stefan and Thayabaran, Darmiga and Braithwaite, Irene and Bénamara, Clément and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study.\n \n \n \n\n\n \n Power, S.; Williams, M.; Semprini, A.; Munro, C.; Caswell-Smith, R.; Pilcher, J.; Holliday, M.; Fingleton, J.; Harper, J.; and Hurst, R.\n\n\n \n\n\n\n BMJ open, 7(3): e013850. 2017.\n Number: 3 Publisher: British Medical Journal Publishing Group\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{power_rct_2017,\n\ttitle = {{RCT} of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study},\n\tvolume = {7},\n\tissn = {2044-6055},\n\tnumber = {3},\n\tjournal = {BMJ open},\n\tauthor = {Power, Sharon and Williams, Mathew and Semprini, Alex and Munro, Claire and Caswell-Smith, Rachel and Pilcher, Janine and Holliday, Mark and Fingleton, James and Harper, Jacquie and Hurst, Roger},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: British Medical Journal Publishing Group},\n\tpages = {e013850},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n New Zealand asthma guidelines updated.\n \n \n \n\n\n \n Beasley, R.; and Hancox, R. J\n\n\n \n\n\n\n The New Zealand Medical Journal (Online), 130(1466): 7–9. 2017.\n Number: 1466 Publisher: New Zealand Medical Association (NZMA)\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_new_2017,\n\ttitle = {New {Zealand} asthma guidelines updated},\n\tvolume = {130},\n\tissn = {1175-8716},\n\tnumber = {1466},\n\tjournal = {The New Zealand Medical Journal (Online)},\n\tauthor = {Beasley, Richard and Hancox, Robert J},\n\tyear = {2017},\n\tnote = {Number: 1466\nPublisher: New Zealand Medical Association (NZMA)},\n\tpages = {7--9},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2016\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Validation of a metered dose inhaler electronic monitoring device: Implications for asthma clinical trial use.\n \n \n \n\n\n \n Pilcher, J.; Holliday, M.; Ebmeier, S.; McKinstry, S.; Messaoudi, F.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open Respiratory Research, 3: e000128. 2016.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{pilcher_validation_2016,\n\ttitle = {Validation of a metered dose inhaler electronic monitoring device: {Implications} for asthma clinical trial use},\n\tvolume = {3},\n\tdoi = {10.1136/bmjresp-2016-000128},\n\tjournal = {BMJ Open Respiratory Research},\n\tauthor = {Pilcher, Janine and Holliday, Mark and Ebmeier, Stefan and McKinstry, Steve and Messaoudi, Fatiha and Weatherall, Mark and Beasley, Richard},\n\tyear = {2016},\n\tpages = {e000128},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Reference ranges for serum periostin in a population without asthma or copd.\n \n \n \n\n\n \n Caswell-Smith, R.; Hosking, A.; Cripps, T.; Holweg, C.; Matthews, J; Holliday, M.; Maillot, C.; Fingleton, J.; Weatherall, M.; Braithwaite, I.; and Beasley, R.\n\n\n \n\n\n\n Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 46. 2016.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{caswell-smith_reference_2016,\n\ttitle = {Reference ranges for serum periostin in a population without asthma or copd},\n\tvolume = {46},\n\tdoi = {10.1111/cea.12763},\n\tjournal = {Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},\n\tauthor = {Caswell-Smith, Rachel and Hosking, Alexander and Cripps, Terrianne and Holweg, Cécile and Matthews, J and Holliday, Mark and Maillot, Corentin and Fingleton, James and Weatherall, Mark and Braithwaite, Irene and Beasley, Richard},\n\tyear = {2016},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.\n \n \n \n\n\n \n Braithwaite, I.; Williams, M.; Power, S.; Pilcher, J.; Weatherall, M.; Baines, A.; Moynihan, J.; Kempsford, R.; and Beasley, R.\n\n\n \n\n\n\n Respiratory Medicine, 119: 115–121. 2016.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{braithwaite_randomised_2016,\n\ttitle = {Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma},\n\tvolume = {119},\n\tdoi = {10.1016/j.rmed.2016.09.006},\n\tjournal = {Respiratory Medicine},\n\tauthor = {Braithwaite, Irene and Williams, Mathew and Power, Sharon and Pilcher, Janine and Weatherall, Mark and Baines, Amanda and Moynihan, Jackie and Kempsford, Rodger and Beasley, Richard},\n\tyear = {2016},\n\tpages = {115--121},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Pilot study of feasibility of a randomised controlled trial of asthma risk with paracetamol versus ibuprofen use in infancy.\n \n \n \n\n\n \n Riley, J.; Hunt, A.; McDouall, A.; Waqanivavalagi, S.; Braithwaite, I.; Weatherall, M.; Stanley, T.; Beasley, R.; Mitchell, E.; and R Dalziel, S.\n\n\n \n\n\n\n The New Zealand medical journal, 129: 30–42. 2016.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{riley_pilot_2016,\n\ttitle = {Pilot study of feasibility of a randomised controlled trial of asthma risk with paracetamol versus ibuprofen use in infancy},\n\tvolume = {129},\n\tjournal = {The New Zealand medical journal},\n\tauthor = {Riley, Judith and Hunt, Anna and McDouall, Alice and Waqanivavalagi, Steve and Braithwaite, Irene and Weatherall, Mark and Stanley, Thorsten and Beasley, Richard and Mitchell, Edwin and R Dalziel, Stuart},\n\tyear = {2016},\n\tpages = {30--42},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2015\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Three-month validation of a turbuhaler electronic monitoring device: Implications for asthma clinical trial use.\n \n \n \n\n\n \n Pilcher, J.; Shirtcliffe, P.; Patel, M.; McKinstry, S.; Cripps, T.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open Respiratory Research, 2: e000097. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{pilcher_three-month_2015,\n\ttitle = {Three-month validation of a turbuhaler electronic monitoring device: {Implications} for asthma clinical trial use},\n\tvolume = {2},\n\tdoi = {10.1136/bmjresp-2015-000097},\n\tjournal = {BMJ Open Respiratory Research},\n\tauthor = {Pilcher, Janine and Shirtcliffe, Philippa and Patel, Mitesh and McKinstry, Steve and Cripps, Terrianne and Weatherall, Mark and Beasley, Richard},\n\tyear = {2015},\n\tpages = {e000097},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Siblings, asthma, rhinoconjunctivitis and eczema: a worldwide perspective from the International Study of Asthma and Allergies in Childhood.\n \n \n \n\n\n \n Strachan, D P; Aït‐Khaled, N; Foliaki, S; Mallol, J; Odhiambo, J; Pearce, N; Williams, H C; and Group, I. P. T. S.\n\n\n \n\n\n\n Clinical & Experimental Allergy, 45(1): 126–136. 2015.\n Number: 1 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{strachan_siblings_2015,\n\ttitle = {Siblings, asthma, rhinoconjunctivitis and eczema: a worldwide perspective from the {International} {Study} of {Asthma} and {Allergies} in {Childhood}},\n\tvolume = {45},\n\tissn = {0954-7894},\n\tnumber = {1},\n\tjournal = {Clinical \\& Experimental Allergy},\n\tauthor = {Strachan, D P and Aït‐Khaled, N and Foliaki, S and Mallol, J and Odhiambo, J and Pearce, N and Williams, H C and Group, ISAAC Phase Three Study},\n\tyear = {2015},\n\tnote = {Number: 1\nPublisher: Wiley Online Library},\n\tpages = {126--136},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Risk factors for asthma: Is prevention possible?.\n \n \n \n\n\n \n Beasley, R.; Semprini, A.; and Mitchell, E.\n\n\n \n\n\n\n Lancet (London, England), 386: 1075–1085. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_risk_2015,\n\ttitle = {Risk factors for asthma: {Is} prevention possible?},\n\tvolume = {386},\n\tdoi = {10.1016/S0140-6736(15)00156-7},\n\tjournal = {Lancet (London, England)},\n\tauthor = {Beasley, Richard and Semprini, Alex and Mitchell, Edwin},\n\tyear = {2015},\n\tpages = {1075--1085},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Randomized controlled trial of asthma risk with paracetamol use in infancy–a feasibility study.\n \n \n \n\n\n \n Riley, J; Braithwaite, I; Shirtcliffe, P; Caswell‐Smith, R; Hunt, A; Bowden, V; Power, S; Stanley, T; Crane, J; and Ingham, T\n\n\n \n\n\n\n Clinical & Experimental Allergy, 45(2): 448–456. 2015.\n Number: 2 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{riley_randomized_2015,\n\ttitle = {Randomized controlled trial of asthma risk with paracetamol use in infancy–a feasibility study},\n\tvolume = {45},\n\tissn = {0954-7894},\n\tnumber = {2},\n\tjournal = {Clinical \\& Experimental Allergy},\n\tauthor = {Riley, J and Braithwaite, I and Shirtcliffe, P and Caswell‐Smith, R and Hunt, A and Bowden, V and Power, S and Stanley, T and Crane, J and Ingham, T},\n\tyear = {2015},\n\tnote = {Number: 2\nPublisher: Wiley Online Library},\n\tpages = {448--456},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2014\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n The association between paracetamol use and asthma: Causation or coincidence?.\n \n \n \n\n\n \n Weatherall, M.; Ioannides, S.; Braithwaite, I.; and Beasley, R.\n\n\n \n\n\n\n Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 45. 2014.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{weatherall_association_2014,\n\ttitle = {The association between paracetamol use and asthma: {Causation} or coincidence?},\n\tvolume = {45},\n\tdoi = {10.1111/cea.12410},\n\tjournal = {Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},\n\tauthor = {Weatherall, Mark and Ioannides, Sally and Braithwaite, Irene and Beasley, Richard},\n\tyear = {2014},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Randomized Controlled Trial Of Asthma Risk With Paracetamol Use In Infancy - A Feasibility Study.\n \n \n \n\n\n \n Riley, J.; Braithwaite, I.; Shirtcliffe, P.; Caswell-Smith, R.; Hunt, A.; Bowden, V.; Power, S.; Stanley, T.; Crane, J.; Ingham, T.; Weatherall, M.; Mitchell, E.; and Beasley, R.\n\n\n \n\n\n\n Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 45. 2014.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{riley_randomized_2014,\n\ttitle = {Randomized {Controlled} {Trial} {Of} {Asthma} {Risk} {With} {Paracetamol} {Use} {In} {Infancy} - {A} {Feasibility} {Study}.},\n\tvolume = {45},\n\tdoi = {10.1111/cea.12433},\n\tjournal = {Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},\n\tauthor = {Riley, Judith and Braithwaite, Irene and Shirtcliffe, Philippa and Caswell-Smith, Rachel and Hunt, Anna and Bowden, Vanessa and Power, Sharon and Stanley, Thorsten and Crane, Julian and Ingham, Tristram and Weatherall, Mark and Mitchell, Edwin and Beasley, Richard},\n\tyear = {2014},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Randomised placebo-controlled study of the effect of paracetamol on asthma severity in adults.\n \n \n \n\n\n \n Ioannides, S.; Williams, M.; Jefferies, S.; Perrin, K.; Weatherall, M.; Siebers, R.; Crane, J.; Patel, M.; Travers, J.; Shirtcliffe, P.; and Beasley, R.\n\n\n \n\n\n\n BMJ open, 4: e004324. 2014.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{ioannides_randomised_2014,\n\ttitle = {Randomised placebo-controlled study of the effect of paracetamol on asthma severity in adults},\n\tvolume = {4},\n\tdoi = {10.1136/bmjopen-2013-004324},\n\tjournal = {BMJ open},\n\tauthor = {Ioannides, Sally and Williams, Mathew and Jefferies, Sarah and Perrin, Kyle and Weatherall, Mark and Siebers, Robert and Crane, Julian and Patel, Mitesh and Travers, Justin and Shirtcliffe, Philippa and Beasley, Richard},\n\tyear = {2014},\n\tpages = {e004324},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Predictors of Severe Exacerbations, Poor Asthma Control, and β-Agonist Overuse in Asthma for Patients with Asthma.\n \n \n \n\n\n \n Patel, M.; Pilcher, J.; Reddel, H.; Qi, V.; Mackey, B.; Tranquilino, T.; Shaw, D.; Black, P.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 2. 2014.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{patel_predictors_2014,\n\ttitle = {Predictors of {Severe} {Exacerbations}, {Poor} {Asthma} {Control}, and β-{Agonist} {Overuse} in {Asthma} for {Patients} with {Asthma}},\n\tvolume = {2},\n\tdoi = {10.1016/j.jaip.2014.06.001},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Patel, Mitesh and Pilcher, Janine and Reddel, Helen and Qi, Victoria and Mackey, Bill and Tranquilino, Tyronne and Shaw, Dominick and Black, Peter and Weatherall, Mark and Beasley, Richard},\n\tyear = {2014},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2013\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n USE OF RELIABLE ELECTRONIC MONITORS IS THE OPTIMAL METHOD TO ASSESS PATTERNS OF INHALED ASTHMA MEDICATION USE.\n \n \n \n\n\n \n Pilcher, J; Patel, M; Pritchard, A; Black, P; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 18: 45. 2013.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{pilcher_use_2013,\n\ttitle = {{USE} {OF} {RELIABLE} {ELECTRONIC} {MONITORS} {IS} {THE} {OPTIMAL} {METHOD} {TO} {ASSESS} {PATTERNS} {OF} {INHALED} {ASTHMA} {MEDICATION} {USE}},\n\tvolume = {18},\n\tjournal = {Respirology},\n\tauthor = {Pilcher, J and Patel, M and Pritchard, A and Black, P and Weatherall, Mark and Beasley, Richard},\n\tyear = {2013},\n\tpages = {45},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Use of Metered-Dose Inhaler Electronic Monitoring in a Real-World Asthma Randomized Controlled Trial.\n \n \n \n\n\n \n Patel, M.; Pilcher, J.; Travers, J.; Perrin, K.; Shaw, D.; Black, P.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n The journal of allergy and clinical immunology in practice, 1: 83–91. 2013.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{patel_use_2013,\n\ttitle = {Use of {Metered}-{Dose} {Inhaler} {Electronic} {Monitoring} in a {Real}-{World} {Asthma} {Randomized} {Controlled} {Trial}},\n\tvolume = {1},\n\tdoi = {10.1016/j.jaip.2012.08.004},\n\tjournal = {The journal of allergy and clinical immunology in practice},\n\tauthor = {Patel, Mitesh and Pilcher, Janine and Travers, Justin and Perrin, Kyle and Shaw, Dominick and Black, Peter and Weatherall, Mark and Beasley, Richard},\n\tyear = {2013},\n\tpages = {83--91},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n SINGLE BUDESONIDE/FORMOTEROL INHALER AS MAINTENANCE AND RELIEVER THERAPY IS BENEFICIAL IN MAORI ASTHMA.\n \n \n \n\n\n \n Pilcher, J; Patel, M; Smith, A; Davies, C.; Harwood, M.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 18: 44. 2013.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{pilcher_single_2013,\n\ttitle = {{SINGLE} {BUDESONIDE}/{FORMOTEROL} {INHALER} {AS} {MAINTENANCE} {AND} {RELIEVER} {THERAPY} {IS} {BENEFICIAL} {IN} {MAORI} {ASTHMA}},\n\tvolume = {18},\n\tjournal = {Respirology},\n\tauthor = {Pilcher, J and Patel, M and Smith, A and Davies, Cheryl and Harwood, Matire and Weatherall, Mark and Beasley, Richard},\n\tyear = {2013},\n\tpages = {44},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Short-Acting β-Agonist Use As a Marker of Current Asthma Control.\n \n \n \n\n\n \n Patel, M.; Pilcher, J.; Munro, C.; Hosking, A.; Pritchard, A.; Shaw, D.; Black, P.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 1: 370–377. 2013.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{patel_short-acting_2013,\n\ttitle = {Short-{Acting} β-{Agonist} {Use} {As} a {Marker} of {Current} {Asthma} {Control}},\n\tvolume = {1},\n\tdoi = {10.1016/j.jaip.2013.04.008},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Patel, Mitesh and Pilcher, Janine and Munro, Claire and Hosking, Alexander and Pritchard, Alison and Shaw, Dominick and Black, Peter and Weatherall, Mark and Beasley, Richard},\n\tyear = {2013},\n\tpages = {370--377},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2012\n \n \n (3)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n The association between tobacco and the risk of asthma, rhinoconjunctivitis and eczema in children and adolescents: analyses from Phase Three of the ISAAC programme.\n \n \n \n\n\n \n Mitchell, E.; Beasley, R.; Keil, U.; Montefort, S.; and Odhiambo, J.\n\n\n \n\n\n\n Thorax, 67: 941–949. 2012.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{mitchell_association_2012,\n\ttitle = {The association between tobacco and the risk of asthma, rhinoconjunctivitis and eczema in children and adolescents: analyses from {Phase} {Three} of the {ISAAC} programme},\n\tvolume = {67},\n\tdoi = {10.1136/thoraxjnl-2011-200901},\n\tjournal = {Thorax},\n\tauthor = {Mitchell, Edwin and Beasley, Richard and Keil, Ulrich and Montefort, Stephen and Odhiambo, Joseph},\n\tyear = {2012},\n\tpages = {941--949},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: Implications for asthma clinical trial use.\n \n \n \n\n\n \n Patel, M.; Pilcher, J.; Chan, A.; Perrin, K.; Black, P.; and Beasley, R.\n\n\n \n\n\n\n The Journal of allergy and clinical immunology, 130. 2012.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{patel_six-month_2012,\n\ttitle = {Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: {Implications} for asthma clinical trial use},\n\tvolume = {130},\n\tdoi = {10.1016/j.jaci.2012.06.037},\n\tjournal = {The Journal of allergy and clinical immunology},\n\tauthor = {Patel, Mitesh and Pilcher, Janine and Chan, Amy and Perrin, Kyle and Black, Peter and Beasley, Richard},\n\tyear = {2012},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Restriction of LABA use to combination ICS/LABA inhaler therapy in asthma.\n \n \n \n\n\n \n Beasley, R.; Fingleton, J.; and Weatherall, M.\n\n\n \n\n\n\n Thorax, 68. 2012.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_restriction_2012,\n\ttitle = {Restriction of {LABA} use to combination {ICS}/{LABA} inhaler therapy in asthma},\n\tvolume = {68},\n\tdoi = {10.1136/thoraxjnl-2012-202483},\n\tjournal = {Thorax},\n\tauthor = {Beasley, Richard and Fingleton, James and Weatherall, Mark},\n\tyear = {2012},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2011\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma.\n \n \n \n\n\n \n Perrin, K.; Wijesinghe, M.; Healy, B.; Wadsworth, K.; Bowditch, R.; Bibby, S.; Baker, T.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Thorax, 66: 937–941. 2011.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{perrin_randomised_2011,\n\ttitle = {Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma},\n\tvolume = {66},\n\tdoi = {10.1136/thx.2010.155259},\n\tjournal = {Thorax},\n\tauthor = {Perrin, Kyle and Wijesinghe, Meme and Healy, Bridget and Wadsworth, Kirsten and Bowditch, Richard and Bibby, Susan and Baker, Tanya and Weatherall, Mark and Beasley, Richard},\n\tyear = {2011},\n\tpages = {937--941},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2005\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Efficacy of bupropion in the indigenous Maori population in New Zealand.\n \n \n \n \n\n\n \n Holt, S\n\n\n \n\n\n\n Thorax, 60(2): 120–123. February 2005.\n Number: 2\n\n\n\n
\n\n\n\n \n \n \"EfficacyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{holt_efficacy_2005,\n\ttitle = {Efficacy of bupropion in the indigenous {Maori} population in {New} {Zealand}},\n\tvolume = {60},\n\tissn = {0040-6376},\n\turl = {http://thorax.bmj.com/cgi/doi/10.1136/thx.2004.030239},\n\tdoi = {10.1136/thx.2004.030239},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-07-13},\n\tjournal = {Thorax},\n\tauthor = {Holt, S},\n\tmonth = feb,\n\tyear = {2005},\n\tnote = {Number: 2},\n\tpages = {120--123},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2000\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Asthma morbidity 6 yrs after an effective asthma self-management programme in a Maori community.\n \n \n \n \n\n\n \n D'souza, W.; Slater, T; Fox, C; Fox, B; Te Karu, H; Gemmell, T; Ratima, M.; Pearce, N.; and Beasley, R.\n\n\n \n\n\n\n European Respiratory Journal, 15(3): 464–469. March 2000.\n Number: 3\n\n\n\n
\n\n\n\n \n \n \"AsthmaPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{dsouza_asthma_2000,\n\ttitle = {Asthma morbidity 6 yrs after an effective asthma self-management programme in a {Maori} community},\n\tvolume = {15},\n\tissn = {0903-1936, 1399-3003},\n\turl = {http://erj.ersjournals.com/content/15/3/464},\n\tdoi = {10.1034/j.1399-3003.2000.15.07.x},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-07-13},\n\tjournal = {European Respiratory Journal},\n\tauthor = {D'souza, W.j and Slater, T and Fox, C and Fox, B and Te Karu, H and Gemmell, T and Ratima, M.m and Pearce, N.e and Beasley, R.b},\n\tmonth = mar,\n\tyear = {2000},\n\tnote = {Number: 3},\n\tpages = {464--469},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 1993\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Trial of an asthma action plan in the Maori community of the Wairarapa.\n \n \n \n\n\n \n Beasley, R.; D'Souza, W.; Te Karu, H.; Fox, C.; Harper, M.; Robson, B.; Howden-Chapman, P.; Crane, J.; Burgess, C.; and Woodman, K.\n\n\n \n\n\n\n The New Zealand Medical Journal, 106(961): 336–338. August 1993.\n Number: 961\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n
@article{beasley_trial_1993,\n\ttitle = {Trial of an asthma action plan in the {Maori} community of the {Wairarapa}},\n\tvolume = {106},\n\tissn = {0028-8446},\n\tabstract = {AIMS: An asthma action plan has been tested in a study conducted by Wairarapa Maori community health workers and the Wellington asthma research group. There were several distinctive features of the project, including the programme of marae-based asthma clinics, and the partnership between the researchers and the Maori community groups. This paper describes the process by which the study was conducted since this experience may be relevant to future Maori health research projects.\nMETHODS: The programme was launched with a series of hui at marae in the Wairarapa, and marae-based clinics were set up. These were followed up by further support from the Maori community health workers who helped people to keep diaries to monitor their asthma, and generally maintained contact. The severity of asthma in the participants was compared for a two-month period before the action plan was introduced, and for a four-month period after the plan was introduced.\nRESULTS: There was a high participation rate, with 91\\% (63/69) of participants finishing the programme, 75\\% of whom adequately completed their daily asthma diaries. Asthma control improved significantly in the participants. They commented positively on the programme, and particularly on the marae-based clinics.\nCONCLUSIONS: The study was successful in terms of participation in the marae-based clinics, acceptance and use of the plan, and improvement in asthma control of the participants. The findings indicate what can be achieved when researchers and Maori community groups work in partnership.},\n\tlanguage = {eng},\n\tnumber = {961},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Beasley, R. and D'Souza, W. and Te Karu, H. and Fox, C. and Harper, M. and Robson, B. and Howden-Chapman, P. and Crane, J. and Burgess, C. and Woodman, K.},\n\tmonth = aug,\n\tyear = {1993},\n\tpmid = {8341475},\n\tnote = {Number: 961},\n\tkeywords = {Asthma, Community Health Workers, European Continental Ancestry Group, Humans, New Zealand, Oceanic Ancestry Group, Patient Acceptance of Health Care, Patient Education as Topic, Program Evaluation},\n\tpages = {336--338},\n}\n\n
\n
\n\n\n
\n AIMS: An asthma action plan has been tested in a study conducted by Wairarapa Maori community health workers and the Wellington asthma research group. There were several distinctive features of the project, including the programme of marae-based asthma clinics, and the partnership between the researchers and the Maori community groups. This paper describes the process by which the study was conducted since this experience may be relevant to future Maori health research projects. METHODS: The programme was launched with a series of hui at marae in the Wairarapa, and marae-based clinics were set up. These were followed up by further support from the Maori community health workers who helped people to keep diaries to monitor their asthma, and generally maintained contact. The severity of asthma in the participants was compared for a two-month period before the action plan was introduced, and for a four-month period after the plan was introduced. RESULTS: There was a high participation rate, with 91% (63/69) of participants finishing the programme, 75% of whom adequately completed their daily asthma diaries. Asthma control improved significantly in the participants. They commented positively on the programme, and particularly on the marae-based clinics. CONCLUSIONS: The study was successful in terms of participation in the marae-based clinics, acceptance and use of the plan, and improvement in asthma control of the participants. The findings indicate what can be achieved when researchers and Maori community groups work in partnership.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);